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ABSTRACT OF THE DISSERTATION
IMPACT OF SAB-MEDIATED SIGNALING ON GLIOBLASTOMA AND
NEUROBLASTOMA METABOLISM
by
Monica Rodriguez Silva
Florida International University, 2018
Miami, Florida
Professor Jeremy W. Chambers, Major Professor
Glioblastoma (GBM) is the most common and aggressive type of brain cancer,
with an average life expectancy of 15 months. The standard of care for GBM,
surgery accompanied by radiation and chemotherapy (temozolomide-TMZ), has
not changed in over 10 years illustrating the need for new and efficacious
treatments. Therefore, it is imperative to improve our knowledge of GBM
physiology

to

understand

the

mechanisms

driving

recurrence

and

chemoresistance so that more effective therapeutic options can be developed.
Mitochondria-cell communication is key to monitor and maintain both mitochondrial
and cellular health, and signaling events on the outer mitochondrial membrane
(OMM) have emerged as a crucial signal integration site for cellular responses.
Consequently, proteins on the OMM are crucial to determining cellular survival and
dictating organelle physiology. Thus, the goal of our current study is to evaluate
OMM proteins to determine how alterations in organelle regulation may impact
CNS tumor biology. We first measured the concentrations of Bcl-2 family proteins
on mitochondria from ten continuous GBM cell lines and correlated the protein
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levels to IC50 values of genotoxic agents TMZ and irinotecan. We found that Bcl-2
levels corresponded to chemoresistance, while increased Bim concentrations
promoted chemosensitivity. In contrast to our studies in gynecological cancers, the
concentrations of the pro-dysfunction OMM scaffold protein Sab had no impact on
chemosensitivity of the GBM cell lines, despite diminished Sab expression in GBM
patients. However, we identified a novel truncated variant of Sab in the GBM cell
lines. We found that GBM cells expressing only full-length Sab had a slower
proliferation rate than those with the variant, which could be attributed to increased
glycolysis in GBM cells expressing the Sab variant. To determine if the lack of Sabmediated apoptosis was consistent across CNS tumors, we analyzed publiclyavailable patient data and found that Sab expression is down-regulated in
neuroblastoma patients, a pediatric malignancy responsible for 12% of childhood
cancer deaths. We found that that inhibiting Sab-mediated signaling in human
neuroblastoma (SH-SY5Y cells) enhanced oxidative phosphorylation in a pyruvate
dehydrogenase-dependent manner, increased BCl-2 levels (pro-survival),
decreased Bim concentrations (pro-apoptotic), and promoted chemoresistance.
Furthermore, examination of additional neuroblastoma cells derived from CNS
tumors revealed that Sab levels correspond to proliferation rate, metabolic
phenotype, and chemosensitivity. Our studies demonstrate the importance of
OMM signaling in CNS tumor physiology and emphasizes the importance of
cellular context to the outcomes of OMM signaling events.
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CHAPTER I
Literature Review

1

Central Nervous System Malignancies
Cancers that affect brain and spinal cord tissue are considered central nervous
system (CNS) tumors. Using an integrated system of both phenotypic and
genotypic characteristics, CNS tumors can be classified as diffused astrocytic and
oligodendroglial tumors, neuronal and mixed neuronal glial tumors, tumors of the
pineal region, embryonal tumors, ependymal tumors, choroid plexus tumors,
meningiomas, cranial and paraspinal nerves tumors, melanocytic tumors,
lymphomas, mesenchymal non-meningothelial tumors, histiocytic tumors, germ
cell tumors, tumors of the sellar region and metastatic tumors. For the purpose of
our research, the focus will be on glioblastoma (GBM), a type of diffused astrocytic
and oligodendroglial tumor, and neuroblastoma a kind of embryonal tumor (Louis
et al., 2016).
1. Glioblastoma
Glioblastoma (GBM) is the most aggressive and common type of primary brain
tumor in adults, patient survival is generally less than 15 months following
diagnosis (Ostrom et al., 2016). GBM is notorious for the extensive cellular
heterogeneity within a tumor, which is even more complex when one considers
that the etiology of GBM is unknown. GBMs are believed to originated from either
adult neural stem cells or glial cells, specifically astrocytes (Alcantara Llaguno et
al., 2016; Phillips et al., 2006). The clinical presentation of GBM varies depending
on size, location, and regions of the brain affected. The areas of the brain impacted
by GBM lead to clinical symptoms that often precipitate a diagnosis, but only after
the tumor has grown significantly. Most patients will present headaches, increased
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intercranial pressure and focal or progressive neurological deficits (M. E. Davis,
2016).
1.1 Statistics
The National Cancer Institute (NCI) estimates that brain tumors account for 85%90% of all primary CNS tumors, anaplastic astrocytomas and glioblastomas are
the most common and represent 38% of cases of primary brain tumors (Noone et
al., 2018). GBM commonly affects older adults, with the median age of diagnosis
being 64 years old, and rarely affects children (Thakkar et al., 2014). The American
Brain Tumor Association (ABTA) estimates the median survival for patients treated
concurrently with temozolomide (TMZ) and radiotherapy to be 14.6 months, twoyear survival is around 30%, however less than 10% of patients will survive five
years or longer (Stupp et al., 2015). Thus, it is imperative to improve the collective
knowledge regarding GBM pathogenesis from both the basic science and clinical
perspective to improve diagnostic strategies and develop more efficacious
treatment options for GBM patients.
1.2 GBM stages and classification
The World Health Organization (WHO) classifies CNS tumors according to a
malignancy scale based on the tumor’s histologic features. CNS tumor grades are
defined as follows (Kleihues et al., 1993):
a. Grade I: slow proliferating tumors that have low invasive potential, tumors
are localized, and surgical resection alone is sufficient treatment.
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b. Grade II: tumors show slow proliferating rates but have more invasive
potential than grade I tumors, overtime tumors are more likely to recur and
become more aggressive.
c. Grade III: tumors are highly proliferative, have increased invasive potential
and show histologic evidence of malignancy, such as nuclear atypia.
d. Grade IV: tumors are highly proliferative, prone to necrosis, and show rapid
preoperative progression and postoperative reoccurrence. All GBM tumors
are considered to be grade IV.
GBMs can be further classified into four subtypes based on gene expression
patterns and genomic alterations, this classification is clinically relevant and allows
better patient stratification for targeted therapies. The four molecular subtypes are
described below (Table 1) (Verhaak et al., 2010).
1.3 GBM features
GBMs exhibits common hallmarks of cancer including genomic instability, ability
to diffusely infiltrate tissue, increased resistance to apoptosis, unrestricted
proliferation, and dysregulated angiogenesis (Hanahan and R. A. Weinberg,
2011). These characteristics, combined with significant tumor heterogeneity, and
the constant presence of cancer stem cells, make GBMs a particularly complex
and difficult disease to treat malignancy (Furnari et al., 2007) Specific genetic
modifications that occur in GBMs sustain tumor biology and alter metabolism,
collectively, these alterations enhance the survival of GBM tumor cells in the
stressful tumor microenvironment.
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Comprehensive genomic analysis of GBM samples for The Cancer Genome Atlas
(TCGA) project determine alterations in the three main pathways, namely aberrant
activation of receptor tyrosine kinase (RTK)/ Ras/phosphatidyl inositol 3-kinase
Table 1. Gene expression based molecular classification of GBM subtypes.
(Adapted from (Verhaak et al., 2010)
GBM
SUBTYPE
Classical

MOLECULAR SIGNATURE
Chromosome 7 amplification paired with chromosome 10 loss
High level EGFR amplification
No TP53 mutations
Focal 9p21.3 homozygous deletion, target CDKN2A
High expression of stem cell marker Nes, and signaling
pathways Notch and Sonic hedgehog

Mesenchymal

Focal 17q11.2 hemizygous deletion, target NF1
Expression of mesenchymal marker CHI3L
Expression of astrocytic markers CD44 and MERTK
Increased expression of TRADD, RELB, TNFRSF1A (NF-kB
pathway)

Proneural

PDGFRA alterations, focal amplifications at 4q12 and high
PDGFRA expression
IDH1 point mutations
TP53 loss of heterozygosity and mutations
High expression of oligodendrocytic development genes
PDGFRA, NKX2-2, OLIG2
Low expression of CDKN1A
PIK3CA/PIK3R1 mutations
Expression of proneural development genes SOX, DCS, DLL3,
ASCL1, TCF4

Neural

Expression of neuron markers NEFL, GABRA1, SYT1 and
SLC12A5
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(PI3K)

signaling, and inactivation of tumor suppressor pathways p53 and

retinoblastoma (Rb) (Cancer Genome Atlas Research Network, 2008). Moreover,
amplifications on chromosome 7 (epidermal growth factor receptor - EGFR,
mesenchymal epithelial transition - MET and cyclin dependent kinase 6 - CDK6),
chromosome 12 (cyclin dependent kinase 4 - CDK4 and E3 ubiquitin-protein ligase
MDM2) and chromosome 4 (platelet derived growth factor alpha - PDGFRA) are
the most common, and mutations on the telomerase reverse transcriptase (TERT)
promoter enhance telomere maintenance, promoting sustained cell survival
(Brennan et al., 2013).
Mutations in certain metabolic enzymes, such as isocitrate dehydrogenase (IDH)
or pyruvate kinase M2 (PKM2), facilitate the use of aerobic glycolysis by GBM
tumors. Furthermore, the distinctive metabolites produced by the mutated
enzymes can induce oncogenic changes by affecting epigenetics (Agnihotri and
Zadeh, 2016; Wolf et al., 2010).
Isocitrate dehydrogenases (IDH1, IDH2) produce α-ketoglutarate (α-KG) from
isocitrate and reduce NADP+ to NADPH (Krell et al., 2011). Mutations on the IDH
active site results in 80% reduction of enzymatic activity, decreased levels of α-KG
and a gain of alternative function for the enzyme, which now reduces α-KG in an
NADP-dependent manner to produce 2-hydroxyglutarate (2-HG) (Dang et al.,
2009; Zhao et al., 2009). 2-HG acts as an oncometabolite by inhibiting α-KGdependent histone demethylases resulting in hypermethylation at a large number
of genetic loci, collectively known as the glioma-CpG island methylator phenotype
(G-CIMP) (Noushmehr et al., 2010; Xu et al., 2011). Decreased levels of α-KG
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result in stabilization and increased levels of hypoxia-inducible factor 1-alpha
(HIF1-α), which orchestrates a concerted response within mammalian cells under
hypoxic conditions by inducing the expression of genes involved in angiogenesis
and glucose metabolism (Semenza, 1999; Zhao et al., 2009). Furthermore,
interaction of HIF1-α with nuclear PKM2 promotes transactivation of HIF1-α target
genes such as glucose transporter (GLUT1), lactate dehydrogenase A (LDHA),
and pyruvate dehydrogenase kinase 1 (PDK1). HIF1-α also promotes the
transcription of PKM2 creating a feedforward loop that amplifies the HIF1-α
metabolic reprogramming (Luo et al., 2011).
1.4 Standard of care and current therapies
Treatment for newly diagnosed GBM patients is surgery follow by a combination
of radiotherapy and chemotherapy with temozolomide (TMZ), a DNA alkylating
agent.

Promoter

methylation

status

for

O-6-methylguanine-DNA-

methyltransferase (MGMT) serves as a predictor for patients that would benefit
from TMZ treatment (Hegi et al., 2005). The standard of care for GBM patients has
not changed in more than 10 years, the approach is largely ineffective, and
responses vary greatly between patients. (Hegi et al., 2005; Stupp et al., 2005).
Recently, tumor treating fields (TTFields) have undergone clinical trials for
treatment of newly diagnosed GBM patients (Stupp et al., 2015). These alternating,
intermediate frequency, low-intensity electric fields, disrupt tumor growth by
promoting cell cycle arrest and apoptosis. TTFields in combinations with TMZ
prolong progression-free survival and overall survival (Hottinger et al., 2016).
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2. Neuroblastoma
Neuroblastoma arises from precursor cells of the sympathetic nervous system
derived from the neural crest (Maris et al., 2007). The majority of neuroblastoma
tumors will develop on the adrenal glands, but it can also develop in the abdomen,
chest and neck (Maris et al., 2007). Primary CNS neuroblastoma is a rare type of
intracranial tumor that usually presents during the first five years of life (Bianchi et
al., 2018). CNS neuroblastomas are mostly located in the supratentorial region of
the brain and characteristically show poorly differentiated neuroepithelial cells,
groups of neurocytic cells, variable neuropil-rich stroma. Clinical presentation
varies widely, with seizures and focal neurological deficits being the most common
symptoms (Bianchi et al., 2018).
2.1 Statistics
According to the American Cancer Society (ACS), neuroblastoma is the most
common type of cancer in children younger than one year old, approximately 90%
of the cases are diagnosed before five years of age and it is rarely observed in
people over ten years old (E. Ward et al., 2014). In the United States, according to
the National Cancer Institute (NCI) 650 new cases are diagnosed every year, it
represents 5% of all pediatric cancer diagnoses but it is responsible for up to 12%
of childhood cancer mortality (Bosse and Maris, 2016). The overall five-year
survival rate is 80.2% (1975-2015) (Noone et al., 2018). The age of diagnosis plays
a significant role in survival rates, where the relative survival rate for children
diagnosed before one year old is 91.1%, decreasing to 54.1% for diagnoses
between 15-19 years of age (Noone et al., 2018). Primary CNS neuroblastoma are
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relative rare cases and statistics for this kind of tumor are limited (Bianchi et al.,
2018). Great advances have been made in recent years for treatment of lower risk
cases, however survival rates for children with high risk neuroblastoma remains
under 40% (Bosse and Maris, 2016). These statistics illustrate the need for better
treatment options for children with high risk neuroblastoma.
2.2 Neuroblastoma Stages and Classification
Neuroblastoma is a heterogeneous disease exhibiting considerable variability in
clinical presentation, prognosis and pathogenesis. In order to facilitate diagnosis
the International Neuroblastoma Staging System (INSS), was created to classify
tumors according to disease stage (Brodeur et al., 1993). The INSS tumor stages
are defined as follows (Brodeur et al., 1993):
a. Stage 1: tumor is localized, gross excision is complete, lymph nodes are
microscopically clear of tumor.
b. Stage 2A: tumor is localized, gross excision is incomplete, lymph nodes are
microscopically clear of tumor.
c. Stage 2B: tumor is localized, gross excision is either complete or
incomplete, lymph nodes are positive for tumor.
d. Stage 3: tumor is unilateral, infiltrating the midline (vertebral column) and
unresectable, with or without positive lymph nodes.
e. Stage 4: any primary tumor that has dissemination to other organs,
including but not exclusive to bone, bone marrow, liver and distant lymph
nodes.
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f. Stage 4s: localized tumor as previously described for stages 1, 2 and 2A,
that have disseminated to skin, liver and/or bone marrow, in infants less
than 1 year old.
Additional stratification of patients can be achieved using the guidelines provided
by the International Neuroblastoma Risk Group (INRG) system, which classifies
patients according to their pretreatment risk based on image-defined risk factors
(IDRFs) (Table 2). There are four different groups according to the INRG
classification (Monclair et al., 2009):
a. L1: tumor is localized and confined to one body compartment, vital
structures are not involved.
b. L2: tumors may be present in continuous body compartments and presents
one or more IDRFs.
c. M: tumor presents distant metastases (except as defined for MS).
d. MS: metastatic disease confined to skin, liver, and/or bone marrow. Patient
is greater than18 months.
Furthermore, patient’s prognosis of 5 year event-free survival can be classified into
four different risk groups very low risk (>85%), low (75%-85%), intermediate
(<75%) and high risk (<50%) by combining the INRG classification system with
tumor stage, age of diagnosis, tumor differentiation, histologic category, MYCN
oncogene amplification, chromosome p11 status and DNA ploidy, (Cohn et al.,
2009). The differences in these events culminate in distinct physiological features
of neuroblastoma that ultimately lead to disease heterogeneity.
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Table 2. Image-Defined Risk Factors in Neuroblastoma tumors.
(Adapted from (Monclair et al., 2009)
IDRFs
Ipsilateral extension (2
body compartments)

Tumor Location
Neck-Chest
Chest-Abdomen
Abdomen-Pelvis

Neck

Encases carotid, vertebral artery and/or jugular vein
Extends to base of the skull
Compresses the trachea

Cervico-Thoracic

Encases brachial plexus roots
Encases carotid, vertebral artery and/or subclavian
vessels
Compresses the trachea

Thorax

Encases aorta and/or major branches
Compresses the trachea or principal bronchi
Infiltrates costo-vertebral junction between T9-T12

Thoraco-abdominal
Abdomen/pelvis

Encases aorta and/or vena cava
Infiltrates of the porta hepatis and/or hepatoduodenal
ligament
Encases superior mesenteric artery
Encases origin of the coeliac axis and/or superior
mesenteric artery
Encases aorta and/or vena cava
Encases iliac vessels
Crosses the sciatic notch

Intraspinal extension
Adjacent
organs/structures

Invades more than one third of the spinal canal,
perimedullary leptomeningeal spaces are not visible
and/or spinal cord signal is abnormal
Invades pericardium, diaphragm, kidney,
duodeno-pancreatic block, mesentery
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liver,

2.3 Neuroblastoma features
Specific genetic and biological changes in neuroblastoma tumors transforming
cells to maintain continuous cell proliferation, bypass growth suppressors signals,
attain replicative immortality, promote angiogenesis, evade cell death, avoid
immune destruction and alter cellular metabolism (Hanahan and R. A. Weinberg,
2011).
The most common genetic alteration observed in neuroblastoma is the
amplification of the proto-oncogene MYCN, usually observed in high-risk
neuroblastoma tumors and correlates with advance stages of the disease and less
favorable prognosis (Olsen et al., 2017). Part of the Myc family of transcription
factors, N-Myc (MYCN) is involved in several cellular proposes such as
proliferation, growth, differentiation apoptosis, metabolism, and it plays an
important role in brain development (Beltran, 2014). Several studies have shown
that deregulation of MYCN, either by amplification or overexpression, promotes
tumorigenesis both in neural crest progenitor cells and in mice (Althoff et al., 2015;
Montavon et al., 2014; Schulte et al., 2013; Weiss et al., 1997). Other common
segmental chromosomal aberrations that correlate with prognosis are deletions in
chromosomes 1p, 1q, 3p, 4p or 11q, and gain of chromosome 17q, however the
specific candidates responsible for changes in tumor biology are not known (Bosse
and Maris, 2016).
Familial cases of neuroblastoma are extremely rare accounting for 1-2% of all
neuroblastoma cases, 80% of these cases can be attributed to either a gain of
function mutation on anaplastic lymphoma kinase (ALK) or a loss of function
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mutation on paired-like homeobox 2B (PHOX2B) (Bosse and Maris, 2016).
Constitutive activation of ALK disrupts the balance between differentiation and
proliferation. One of the proposed mechanisms involves the activation of RASmitogen activated protein kinases (MAPK) signaling pathways leading to increased
proliferation. Also, recent evidence suggests that PHOX2B regulates ALK
expression (Cheung and Dyer, 2013). Furthermore, mutations that promote
constitutive activation of the RAS-MAPK signaling pathway are associated with
neuroblastoma relapse (Eleveld et al., 2015).
Telomere lengthening has been observed in high risk neuroblastomas, where
rearrangements in the chromosome region 5p15.33 upregulate transcription of
TERT, and 10% of neuroblastoma cases show loss of function mutations in alpha
thalassemia/mental retardation syndrome X-linked (ATRX), these tumors undergo
alternate lengthening of telomeres which is independent of telomerase activity
(Bosse and Maris, 2016; Peifer et al., 2015).
2.4 Standard of care and current therapies
The standard of care for neuroblastoma patients varies according to the tumors
risk classification. Treatment for patients with low risk tumors is either observation
or surgical resection (Strother et al., 2012). Patients with intermediate risk tumors
receive several chemotherapy cycles with carboplatin, etoposide, doxorubicin and
cyclophosphamide, followed by surgical removal of the primary tumor (Baker et al.,
2010). High risk neuroblastoma requires aggressive treatment that combines
chemotherapy

with

cisplatin,

etoposide,

vincristine,

cyclophosphamide,

doxorubicin and topotecan, followed by surgery (Kushner et al., 1994; Park et al.,
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2011). A round of myeloablative chemotherapy aims to eliminate any residual
disease and it is followed by stem cell transplantation (SCT) to replenish the bone
marrow, common drug combinations used are

carboplatin, etoposide and

melphalan, or busulfan and melphalan (Matthay et al., 1999) (Elborai et al., 2016).
Patients in remission after SCT are treated with dinutuximab, granolucytemacrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and
isotretinoin (Cheung et al., 2012; Yu et al., 2010).
3. Cancer metabolism
All cancers share a common set of features known as the “hallmarks of cancer”,
unrestricted proliferation, evasion of growth suppressors signals and cell death,
induction of angiogenesis, activation of invasion and metastasis, and metabolic
reprogramming, genomic instability introduces genetic diversity that promotes and
sustain the changes necessary for cancer cells to survive. (Hanahan and R. A.
Weinberg, 2011). Mutations in distinct metabolic enzymes change the capacity of
tumor cells to use alternative substrates in comparison to normal tissue.
Collectively, these alterations enhance the survival of tumor cells in a stressful,
oxygen deprived, nutrient restricted environment.
3.1 General
The most widely studied metabolic change in cancer cells is aerobic glycolysis,
also knowns as the “Warburg effect”, where glucose is converted to lactate even
in the presence of oxygen (Bensinger and Christofk, 2012). Even though aerobic
glycolysis seems inefficient in terms of ATP production in comparison to oxidative
phosphorylation, it provides proliferating cancer cells with precursors for
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biosynthesis of macromolecules such as fatty acids, nucleotides, ribose and nonessential amino acids (Vander Heiden et al., 2009). Different mechanisms
orchestrate the transcription upregulation of glycolytic enzymes frequently
observed in cancer cells. PI3K signaling increases glucose uptake via AKT
upregulation of glucose transporter expression (GLUT1), stimulation of hexokinase
(HK) activity and posttranslational stabilization of phosphofructokinase 1 (PFK1)
(Plas et al., 2001; Rathmell et al., 2003). The transcription factor HIF1-a, also
regulated by the PI3K/AKT/mTOR pathway, promotes expression of hexokinase II
(HK-II), pyruvate dehydrogenase kinase (PDK) and lactate dehydrogenase (LDH)
(Courtnay et al., 2015; Roberts and Miyamoto, 2015). The oncogene MYC can
also promote upregulation of glycolytic enzymes and PDK1, while loss of the tumor
suppressor p53 decreases expression of TP53-induced glycolysis and apoptosis
regulator (TIGAR), which in turn decreases oxidative phosphorylation and
increases flux through glycolysis (Bensinger and Christofk, 2012). Furthermore,
some metabolic enzymes switch between isoforms further supporting the cell’s
preference for aerobic glycolysis, for example the splice variant PKM2, normally
expressed embryonically, when expressed in tumor tissues is sufficient to promote
aerobic glycolysis, however knockdown of this isoform and switch to adult PKM1
results in a decrease in glycolytic rate and cell proliferation (Christofk et al., 2008).
Development of cancer cells occurs within an environment where resources are
limited, cancer cells use a wide variety of nutrients in order to fulfill their
requirements (Vander Heiden and DeBerardinis, 2017). In order to synthesize
macromolecules, such as lipids, nucleotides and aminoacids, cancer cells rely on

15

intermediates from the tricarboxylic acid (TCA) cycle. For lipid biosynthesis, citrate
is shuttled outside the mitochondria to be converted into oxaloacetate (OAA) and
acetyl-CoA, changes in protein expression and activity of ATP citrate lyase and
fatty acid synthase are frequently observed in tumors. Furthermore, OAA and aKG supply nonessential aminoacids for protein and nucleotide synthesis
(DeBerardinis et al., 2008). Glutamine oxidation, also known as glutaminolysis,
provides support for bioenergetics and replenishes TCA intermediates (Daye and
Wellen, 2012). Glutamine is readily available in circulation, providing cancer cells
with a source of carbon and nitrogen for bioenergetics, macromolecule synthesis
and cellular homeostasis. Glutaminase (GLS) mediates the conversion of
glutamine to glutamate and an ammonium ion, several cancer types show
preferential expression of the more active splice variant glutaminase C (GAC);
glutamate is further process to a-KG by glutamate dehydrogenase (GLUD) that
also produces NADH and NAPDH supporting the TCA cycle, or alanine
aminotransferase and aspartate aminotransferase, which provide

other

aminoacids that can support different biosynthetic processes (Altman et al., 2016).
3.2 Glioblastoma
Specific genetic modifications that occur in GBMs sustain tumor biology and alter
metabolism, where mutations in distinct metabolic enzymes change the capacity
of tumor cells to use substrates in comparison to normal tissue. Understanding the
metabolically-relevant genetic alterations promoting GBM tumor biology will
provide unique insights that may improve diagnostic and therapeutic approaches.
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3.2.1 Substrate Utilization
Tumor cells utilize substrates distinctly from their normal counterparts to maximize
growth and proliferation. A recent study using carbon-13 NMR spectroscopy in rat
C6 glioma cells, an in vitro model of GBM, revealed the production of lactate from
glucose, consistent with aerobic glycolysis, and consumption of glutamine for
anaplerosis of the tricarboxylic acid (TCA) cycle; in this system both substrates
complement each other to support the high proliferation rates (Portais et al., 1996).
An additional study confirmed that GBM cells use aerobic glycolysis and showed
that exogenous lactate was the main substrate used for oxidative phosphorylation.
The ability of the cells to utilize two distinct sources of lactate could provide a
potential growth advantage (Bouzier et al., 1998).
The human GBM cell line U87 is characterized by low respiration, elevated
glycolytic rates, and increased stability of hypoxia inducible factors HIF-1α and
HIF-2α (Zhou et al., 2011). Studies in U87 cells demonstrated that inhibition of
glycolysis reduced cellular ATP production and resulted in cell death (Blum et al.,
2005; Zhou et al., 2011). Metabolic trace experiments using

13

C-NMR

demonstrated that the GBM cell line SF188 uses glucose for aerobic glycolysis,
produces abundant levels of labeled lactate and alanine, with glucose carbons
entering the TCA cycle as pyruvate through pyruvate dehydrogenase (PDH), which
later contributes to fatty acid synthesis (DeBerardinis et al., 2007). This study also
revealed that SF188 cells use glutamine as anaplerotic nutrient for the TCA cycle
and as a source of NADPH (DeBerardinis et al., 2007). Addiction to glutamine has
been shown in SF188 cells, where glutaminolysis preserves mitochondrial activity,
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replenishes the TCA cycle and contributes to bioenergetics (Wise et al., 2008).
Under hypoxic conditions, the GBM cell line SF188 uses glutamine as a source of
α-ketoglutarate, which generates citrate by isocitrate dehydrogenase 2 (IDH2), an
event required for fatty acid and cholesterol synthesis, protein acetylation and
NADPH production (Wise et al., 2011).
Orthotopic mouse models for primary GBM and 13C-NMR have demonstrated that
glucose is used for glycolysis rather than increased flux through the pentose
phosphate pathway (PPP) as previously suggested by cell-based studies.
Detection of labeled glutamate and γ-aminobutiric acid (GABA) indicated that
glucose was converted to acetyl-CoA and then oxidized in the TCA cycle, showing
that both aerobic glycolysis and oxidative metabolism occur in vivo (Marin-Valencia
et al., 2012a). Furthermore, the presence of labeled lactate, glutamate and
glutamine provided evidence that glucose serves as an anaplerotic nutrient
entering the TCA cycle through pyruvate carboxylase. Labeling of glutamate and
glutamine has been demonstrated to be due to normal turnover of the TCA cycle
and PDH activity in the tumor, however, these tumors do not oxidize glutamine or
require an extracellular supply, since they can synthesize glutamine de novo from
glucose (Marin-Valencia et al., 2012b). Metabolic analysis of human brain tumors
in vivo showed similar results to the orthotopic mouse models, where labeled
glucose supplied to tumors during surgical resection is engaged in glycolysis as
well as oxidation in the TCA cycle, and along with glycine and glutamine synthesis.
In this way, glucose is used for energy supply and for macromolecule precursors
(Maher et al., 2012). A recent study found that orthotopic mouse brain tumors, as
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well as patient GBM tumors, highly expressed acetyl-CoA synthetase enzyme 2
(ACSS2) that catalyzes the conversion of acetate into acetyl-CoA, thus permitting
oxidation of acetate in the TCA cycle (Mashimo et al., 2014).
Multiple GBM model systems are available that display distinct preferences for
metabolic substrates (Table 3). Metabolic differences may be observed in each of
these systems, however, these should be interpreted with caution since they may
not apply to all systems and thus may not translate to what happens in GBM
patients. Thus, it is imperative to develop more precise model systems and
techniques to better understand metabolic differences in GBM tumors that more
accurately represent what happens in patients.

Table 3. GBM model systems and substrate utilization.
MODEL SYSTEM
SUBSTRATE
END PRODUCT
C6 RAT GLIOMA

U87 CELL LINE

Glucose
Glutamine
External Lactate
Glucose

Glutamine

MOUSE ORTHOTOPIC
TUMORS
PATIENT GBM
TUMORS

Glucose

Acetate
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Lactate
TCA cycle anaplerosis
TCA cycle anaplerosis
Lactate
Alanine
TCA cycle – Fatty
synthesis
TCA cycle anaplerosis
Fatty acid synthesis
Cholesterol synthesis
Protein acetylation
Lactate
TCA cycle
Glutamate, GABA
Glutamine
Acetyl-CoA

acid

3.2.2 Isocitrate Dehydrogenase
Isocitrate dehydrogenases (IDH1, IDH2) produce α-KG from isocitrate and reduce
NADP+ to NADPH (Krell et al., 2011). IDH1 and IDH2 are homodimeric, can either
be mitochondrial or cytosolic and can protect the cell against oxidative stress
damage (Jo et al., 2001; S. Y. Kim et al., 2007; Krell et al., 2011; X. Xu et al.,
2004). Interestingly, the IDH1 gene is commonly mutated in patients with
secondary GBMs. Genomic analysis of human GBM tumor samples revealed that
all patients had the same mutation in the IDH1 active site where arginine 132 was
often replaced by a histidine (R132H). IDH1R132H tends to occur in younger
patients, and individuals with this mutation have an improved prognosis, increasing
their median survival to 3.8 years in comparison to 1.1 years for IDH1 wild-type
patients (Parsons et al., 2008). Other glioma patients have the IDH1R100 mutation,
while pediatric glioblastoma patients have the IDH1G97 mutation. Furthermore,
tumors without any IDH1 mutations frequently displayed mutations in the IDH2
gene (P. S. Ward et al., 2011; Yan et al., 2009). IDH2 mutations occurred on the
analogous aminoacid R172 in the active site which was replaced by either a
glycine (R172G), a lysine (R172K) or a methionine (R172M) (Yan et al., 2009).
In vitro studies showed that GBM derived mutations in IDH1 and IDH2 have greater
than 80% reduction of their enzymatic activity when compared to their wild-type
counterparts due to decreased affinity for isocitrate, which results in very limited
enzymatic activity under physiological conditions. Expression of mutant IDH1R132H
in the human GBM cell line U87-MG resulted in decreased levels α-KG in a dosedependent manner. This may be attributed to the fact that IDH1 works as a
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homodimer, expression of IDH1R132H results in dominant inhibition of the wild-type
enzyme by forming heterodimers IDH1wt:IDH1R132H that are unable to catalyze the
production of α-KG (Zhao et al., 2009). However, analysis of patient tumor samples
carrying different IDH1 mutations showed that there were no significant differences
in α-KG levels between mutant samples and tumor samples carrying wild type
IDH1 (Dang et al., 2009). This IDH1 mutation also results in a gain of function
activity for the enzyme, where IDH1 heterodimers reduce α-KG in an NADPdependent manner and produce 2-hydroxyglutarate (2-HG), specifically the Risomer (R)-2-HG (Figure 1). Elevated levels of 2-HG have also been observed both
in GBM cell lines expressing the mutant enzyme as well as in GBM patient samples
harboring the IDH1R132H mutation (Dang et al., 2009). The combination of these
changes may contribute to malignant progression due to several events since αKG is required by prolyl-hydroxylases (PHD) enzymes to promote HIF1-α
degradation, while decreased levels of α-KG result in stabilization and increased
levels of HIF1-α (Zhao et al., 2009). U87 cells stably transfected with IDH1R132H,
result in inhibition of ATP synthase by 2-HG, having decreased ATP levels and
ATP/ADP ratio and decreased mammalian target of rapamycin (mTOR) signaling
(Fu et al., 2015). Furthermore, working as an oncometabolite, 2-HG competitively
inhibits α-KG dependent histone demethylases due to its structural similarity with
α-KG. Expression of IDH1R132H in U87-MG resulted in a decrease of α-KG levels,
an increase in 2-HG levels and an increase in histone methylation. Comparable
results were observed in patients, where tumor samples carrying the IDH1
mutation had significantly higher levels of histone methylation in comparison to
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IDH1-wild type tumor samples (W. Xu et al., 2011). Expression of mutant IDH1
caused hypermethylation of a series of genes in immortalized primary human
astrocytes, as well as in low-grade gliomas and secondary GBMs carrying the
endogenous IDH1 mutation (Turcan et al., 2012). Some genes involved in
glycolysis, including lactate dehydrogenase A (LDHA), are under-expressed in
gliomas, brain tumor stem cells (BTSC) and orthotopic xenografts derived from
BTSC carrying the mutant IDH, due to methylation of the promoter (Chesnelong et
al., 2014).

Figure 1. Metabolic changes resulting from IDH mutations.
IDH heterodimers reduce α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG)
altering GBM metabolism through a series of reactions. Inhibition prolylhydroxylases (PHD) stabilizes HIF1-α and increases PDK1 expression, inhibition
of ATP synthase reduces ATP/ADP ratio inhibiting mTOR signaling, decrease
levels of α-KG results in reduced levels of several aminoacids and TCA cycle
intermediates and increased expression of PC promotes reprogramming of
pyruvate metabolism.
Metabolomics analysis of human oligodendroglioma (HOG) cells expressing either
wild-type IDH1, IDH2 or IDH1R132H, IDH2R172K revealed that cells expressing the
mutant proteins have significant differences in their metabolic profile. Mutations in
IDH caused changes in aminoacid levels, where a significant decrease was
observed in levels of aspartate, glutamate, N-acetylated aminoacids, both reduced
and oxidized glutathione, and TCA cycle intermediates including fumarate, malate,
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and α-KG. These changes were shown to be due to production of 2-HG since
treatment of cells with shRNA against IDH1/2 did not reproduce these altered
metabolic profiles, however, similar changes were observed when cells were
treated with 2-HG (Reitman et al., 2011). Decreased levels of glutamate were not
only observed due to mutant IDH mediated increase flux of α-KG to 2-HG but also
as a result of pyruvate metabolism reprogramming. Accumulation of 2-HG raises
levels of HIF-1α and causes downregulation of pyruvate dehydrogenase (PDH)
activity, which results in decreased decarboxylation of pyruvate into acetyl-CoA
before entering the TCA cycle as well as a generally diminished flux of glucose to
glutamate, as shown using 13C-MRS in U87 cells carrying mutant IDH (IzquierdoGarcia et al., 2015). To support TCA cycle anaplerosis, IDH mutant cells exhibit
increased expression of pyruvate carboxylase (PC), which catalyzes the
conversion of pyruvate into oxaloacetate. Higher expression levels of PC have
been observed both in immortalized human astrocytes as well as in TCGA patient
samples carrying the IDH1R132H mutation (Izquierdo-Garcia et al., 2014).
Understanding the metabolic changes and compensatory mechanisms adopted by
tumors expressing mutant IDH will potentially identify novel therapeutic targets that
will help improve treatment of patients that present these mutations.
3.2.3 HIF1α
The transcription factor Hypoxia-inducible factor 1 (HIF1) orchestrates the
response of mammalian cells under hypoxic conditions inducing the expression of
genes involved in angiogenesis and glucose metabolism (Semenza, 1999). HIF1
activity is regulated by stabilization of the HIF1-α subunit. Under normal oxygen
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conditions, hydroxylation of certain prolines in the oxygen-dependent degradation
(ODD) domain by PHDs results in recruitment of the E3 ubiquitin ligase von HippelLindau tumor suppressor (pVHL) which promotes HIF1-α degradation via the
ubiquitin-proteasome pathway (Huang et al., 1998; Jaakkola et al., 2001).
Activation of HIF1-α leads to increased angiogenesis and promotes invasion and
migration by controlling the expression of several proteins involved in these
processes (Kaur et al., 2005).
During hypoxia, it is well known that PTEN inhibits the accumulation of HIF1-α, as
U87-MG cells conditionally expressing WT or mutant PTEN showed that loss or
mutation of PTEN caused accumulation and stabilization of HIF1-α. Furthermore,
chemical inhibition of phosphatidylinositide-3 kinase (PI3K) or knockdown of AKT
using small interference RNA (siRNA) blocked both accumulation of HIF1-α and
reduced gene expression. Also, knockdown of PTEN in the glioblastoma cell line
LN229 resulted in increased expression of the HIF1-α target genes hexokinase1
(HK1) and the glucose transporter 1 (GLUT1) Hypoxia also mediates epithelial to
mesenchymal transition (EMT) in GBM cell lines U87 and SNB75 via HIF1-α, which
induces the transcription factor zinc finger E-box binding homeobox 1 (ZEB1) that
promotes EMT, prompts the expression of mesenchymal markers fibronectin and
COL5A (collagen, type V, alpha 1) and promotes migration and a more invasive
phenotype. In patient samples, expression of ZEB1 co-localizes with GLUT1, a
marker for hypoxia, and chitinase 3 like-1 (CHI3L-1), a mesenchymal marker, in
the pseudopalisading area surrounding the necrotic foci (Joseph et al., 2015).
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In U87-MG cells, HIF1-α acts as part of an autocrine loop involving insulin-like
growth factor receptor 1 (IGFR1), STAT3 (signal transducers and activators of
transcription) and IGF-II, which together work to induce release of vascular
endothelial growth factor (VEGF) and thus regulate tumor survival. Activation of
IGFR1 promotes activation of STAT3 that leads to stabilization of HIF1-α and IGFII as well as release of VEGF, thus further activating this circuit. Inhibition of IGFR1
activation disrupts the autocrine loop and reduces cell growth (Gariboldi et al.,
2010). Moreover, a recent study using T98G cells demonstrated that STAT3 can
be repressed by GRIM-19 (gene associated with retinoid-interferon-induced
mortality-19) which reduces the levels of HIF1-α. In these cells knockdown of
GRIM-19, increases cell proliferation, and facilitates the switch from mitochondrial
respiration to glycolysis by increasing GLUT-1 levels at the membrane, enzymatic
activity

of

hexokinase

2

(HK2),

pyruvate

kinase

M2

(PKM2)

and

phosphofructokinase (PFK), and phosphorylation levels and subsequent
inactivation of pyruvate dehydrogenase (PDH) (Liu et al., 2013).
In patient-derived glioma-initiating cells (GICs), HIF1-α induces the microRNA
miR-215 by incorporating pri-miRNA-215 into the DROSHA complex for
processing under hypoxic conditions. MiR-215 promotes tumor growth by allowing
GSCs to adapt to hypoxia by targeting KDM1B, a FAD-dependent histone
demethylase of H3K4me1/2. Low expression of KDM1B results in increased
expression of genes involved in hypoxia response, glucose metabolism and
angiogenesis. It should be noted that in patients, reduced levels of KDM1B
correlates with a poor clinical prognosis (Hu et al., 2016).
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U87 spheroids show induction of the fatty acid-binding protein 3 (FABP3) and
FABP7, which are involved in fatty acid uptake, and accumulation of lipid droplets
(LD) in the hypoxic core domain in HIF1-α dependent manner. Inhibition of
FABP3/7 impairs tumor growth in a murine xenograft model, which was associated
with the decreased levels of LDs. This, in turn, leads to increased reactive oxygen
species (ROS) toxicity and decreased cell survival by reducing the amount of ATP
production from fatty acid b-oxidation or glycogen degradation (Bensaad et al.,
2014).
Since HIF1-α orchestrates the response and adaption to a low O2 environment,
which is characteristic of solid tumors and provides a survival advantage by
promoting angiogenesis, migration and invasion, targeting HIF1-α and the
pathways regulated by it, would provide new therapies that may contribute to
increased survival of GBM patients.
3.2.4 EGFR
The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is
responsible for initiating various signal transduction pathways, including
RAS/mitogen-activated protein kinase and PI3K/AKT, which are particularly
relevant to GBM biology. Abnormal activation of EGFR is common in numerous
forms of cancer and usually occurs due to one of the following alterations:
increased levels of EGFR ligands, amplification of EGFR genes, overexpression
of EGFR members (wild-type or mutants), or EGFR-independent activation of
downstream signaling pathways (Nicholas et al., 2006). In GBMs, amplification of
EGFR genes is common and frequently accompanied by gene rearrangement; the
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most common being a deletion of exons 2 to 7. This results in a mutant receptor
with a truncated extracellular domain called EGFRvIII, which is unable to bind to
its ligands and it is constitutively phosphorylated and thus continuously activates
downstream signaling pathways (Gan et al., 2009; Nagane et al., 2001).
The type of activation of EGFR will determine the downstream signaling, where
ligand-dependent activation engages the canonical networks involving ERK and
AKT, while overexpression and constitutive activation of the wild-type receptor lead
to phosphorylation and activation of the transcription factor IRF3 (interferon
regulatory factor 3), which activates a series of survival signals. Importantly,
overexpression of EGFRWT in GBM cell lines U251 and U87, reduces sensitivity to
chemotherapy, however, exposure to EGF sensitizes cells to temozolomide
(Chakraborty et al., 2014).
EGF-mediated stimulation of EGFR induces the expression cyclooxygenase-2
(COX-2) through activation of the p38-MAPK pathway. COX enzymes are crucial
for prostaglandins biosynthesis. COX-2 is inducible as a rapid response to various
stimuli and may play an important role in tumor biology, where in malignant gliomas
increased expression levels correlate with shorter patient survival. In the glioma
cell line SF767, EGF binding to EGFR promotes activation of p38-MAPK, which
then

phosphorylates

protein

kinase

C-delta

(PKC-d)

resulting

in

Sp1

phosphorylation, nuclear translocation and enhanced binding to the COX-2
promoter, followed by increased levels of COX-2 (mRNA and protein). Inhibition of
EGFR kinase activity, p38-MAPK, PKC-d or the transcription factors Sp1/Sp3,
blocks the EGF-dependent induction of COX-2 (K. Xu et al., 2009; K. Xu and Shu,
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2007). COX-2 expression may also be mediated by the nuclear translocation of
EGFR and STAT3, which also controls transcriptional activation of genes like iNOS
(inducible nitric oxide synthase) and c-MYC. In glioma patients, activation of
STAT3 correlates with expression of insulin-like growth factor binding protein 2
(IGFBP2). In GBM cell lines, SNB19 and U87, it was demonstrated that IGFBP2
activates STAT3 and subsequent transcription of STAT3 target genes by activating
and promoting the nuclear accumulation of EGFR (Chua et al., 2016).
Interestingly, EGF activation of EGFR also leads to increased expression of PKM2
but not PKM1. U87 cells overexpressing EGFRvIII exhibit higher levels of PKM2
in comparison to cells U87 overexpressing EGFRWT without EGF stimulation, while
inhibition of EGFR activation by treating cells with AG1478 blocked PKM2
upregulation. PKM2 expression by EGFR activation depends on activation of both
PKCe and nuclear factor kappa enhancer binding protein, correlates with increased
glycolysis and tumorigenesis, and in patients, with the grade of glioma malignancy
(W. Yang et al., 2012a).
In mice with inactive p16Ink4/p19ARF and PTEN, expression of EGFRvIII resulted
in formation of highly aggressive tumors, while expression of EGFRWT was not as
efficient for tumor development. After tumor formation, cells isolated and
stimulated with EGF, resulted in phosphorylation of EGFRWT on residues 920, 992,
1045, 1068, 1148 and 1173, whereas, EGFRvIII only showed autophosphorylation
on residue 992. These differences also resulted in differences between signaling
cascades activated by these two receptors. For example, phosphorylation of
STAT3 in tyrosine 705, or MEK/ERK activation was only observed in EGFRWT

28

cells. EGFRvIII showed constitutive phosphorylation of AKT on Ser-473 while
EGFRWT showed phosphorylation on Thr-308 upon EGF-stimulation. Similarly,
stimulation of EGFRWT cells resulted in activation of mTOR complex 1 (mTORC1)
which was not observed in EGFRvIII expressing cells (Zhu et al., 2009). EGFRvIII
cells show elevated levels of mTORC2 signaling, where activation is sensitive to
changes in metabolite availability, increasing in response to both glucose and
acetate in a dose- and time-dependent manner. Regulation of mTORC2 signaling
depends on acetyl-CoA levels, which provides the acetyl group for Rictor
acetylation and then further increases mTORC2 activity. mTORC2 forms an
autoactivation loop by promoting the phosphorylation and subsequent inactivation
of histone deacetylase (HDAC) class IIa by PKCa, which then maintains Rictor in
its acetylated state. Rictor acetylation in the presence of glucose results in GBM
cells that are resistant to therapies that involve inhibition of EGFR, PI3K or AKT,
since it allows tumor cells to maintain mTORC2 signaling active independent of
upstream stimulation (Masui et al., 2015). Since differential activation of EGFR will
dictate the downstream signaling events and affect the aggressiveness and
adaptability of the tumor, it is critical to understand the potential outcomes linked
to a specific activation event so that we better diagnose patients, since determining
the kind of EGFR perturbation will allow the design of more efficacious treatment
plans.
3.2.5 PKM2
Pyruvate kinase (PK) catalyzes the last and rate-limiting step in glycolysis, the
conversion of phosphoenolpyruvate (PEP) to pyruvate while transferring a high-
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energy phosphate to form ATP. There are two genes and four PK isoforms, the
PKLR gene encodes for the PKL and PKR isoforms and the PKM gene encodes
for PKM1 and PKM2 (Wong et al., 2013). PKM2, the primary isoform expressed in
cancer cells, results from the alternative splicing of exons 9 and 10 from the PKM
gene. Unlike the M1 isoform that forms stable tetramers and is constitutively active,
PKM2 is found both as a dimer or a tetramer and has a lower enzymatic activity.
(Christofk et al., 2008; Dombrauckas et al., 2005). PKM2 requires allosteric
activation, by fructose-1,6-biphosphate (FBP) which promotes the formation of the
more active tetramer form. Tyrosine kinase signaling inhibits the enzyme by
facilitating the release of FBP and switching to the less active dimer conformation
(Wong et al., 2013). Under nutrient-limited conditions, PKM2’s activation depends
on levels of the de novo purine nucleotide synthesis intermediate succinyl-5aminoimidazole-4-carboxamide-1-ribose-5’-phosphate (SAICAR) (K. E. Keller et
al., 2012). In this manner PKM2 regulates glucose metabolism favoring entrance
of pyruvate to the TCA cycle when the enzyme is in the active tetramer form or
aerobic glycolysis when present in the less active dimer form, providing cancer
cells a metabolic advantage that facilitates cell proliferation (Figure 2) (Christofk et
al., 2008; Wong et al., 2013).
PKM1 and PKM2 are differentially expressed, where PKM1 Is expressed in heart,
skeletal muscle, and brain, while PKM2 is expressed in most cells except in adult
liver, muscle and brain (Wong et al., 2013). Analysis of TCGA exon array data
showed that GBM tumors have very low or negative levels of the PKM1-specific
exon 9 in comparison to normal tissue, indicating that a switch occurs between
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expression of PKM1 to PKM2. Moreover, the degree of switching varied depending
on the type of tumor, where the ratio between PKM2/PKM1 is higher in more
undifferentiated mesenchymal

Figure 2. PKM2 promotes aerobic glycolysis through two distinct
mechanisms.
PKM2 reduced enzymatic activity decreases entrance of pyruvate into the TCA
cycle and increases aerobic glycolysis, while EGF activation promotes nuclear
translocation of PKM2 where it can transactivate c-Myc and HIF1-α, therefore
upregulating the expression of glycolytic genes like GLUT1, LDHA, and PDK1.
GBMs than in more differentiated proneural GBMs (Desai et al., 2014).
EGF stimulation in U251 and U87/EGFR cells, or in cancer cells carrying the
EGFRvIII mutant, promotes the ERK activation dependent translocation of PKM2
to the nucleus. PKM2 interacts directly with ERK2 which phosphorylates S37,
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promoting the interaction with peptidyl-prolyl Cis/Trans Isomerase, NIMAInteracting 1 (PIN1) which facilitates PKM2 binding to importin a5 allowing it to be
translocated (W. Yang et al., 2012c). After translocation, PKM2 binds to poly-ADPribose (PAR) and this interaction is required for PKM2 nuclear retention and
activity. On the other hand, inhibition of the PKM2/PAR interaction by blocking
poly-ADP-ribose polymerase-1 (PARP1) prevents PKM2 nuclear localization and
diminishes its nuclear functions (Li et al., 2016). PKM2 interacts with c-Src
phosphorylated b-catenin (Y333) and phosphorylates histone H3 at T11, which is
required for disassociation of histone deacetylase 3 (HDAC3) from the cyclin D1
(CCND1) promoter and histone H3 acetylation and expression of cyclin D1 and cMyc, both of which are important for cell proliferation (W. Yang et al., 2012b; 2011).
PKM2 EGF-induced transactivation of b-catenin also upregulates the c-Mycdependent expression of glycolytic genes GLUT1 and lactate dehydrogenase A
(LDHA) (Figure 2). Depletion of PKM2 using shRNA showed reduced b-catenin
transactivation and reduced EGF-induced expression of cyclin D1, c-Myc, its
downstream genes and the capacity of these cells to perform aerobic glycolysis,
thus showing a reduction in glucose consumption and lactate production (W. Yang
et al., 2012c; 2011). Moreover, intracranial injection of either U87 or U87/EGFRvIII
cells into mice, showed that U87/EGFRvIII produced tumors faster, while depletion
of b-catenin or PKM2, as well as inhibition of c-Src, significantly decreased tumor
growth. Furthermore, treatment of tumors with PARP inhibitor olaparib was
effective at reducing growth in U87/EGFRvIII tumors, but lost efficacy in PKM2depleted tumors (Li et al., 2016; W. Yang et al., 2011). Nuclear PKM2 also
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functions as a coactivator of HIF1-α, this interaction promotes transactivation of
HIF1-α target genes such as GLUT1, LDHA, and pyruvate dehydrogenase kinase
1 (PDK1) (Figure 2); interaction with PHD3 enhances HIF1-α binding by prolylhydroxylating PKM2. HIF1-α also promotes the transcription of PKM2 and PHD3,
creating a feedforward loop that amplifies the HIF1-α metabolic reprogramming
(Luo et al., 2011).
PKM2 activity also influences the oxygen consumption rates and carbon flux into
the TCA cycle in the GBM cell line LN229 when cells are placed in a hypoxic or
nutrient deficient environment. The mitochondrial serine hydroxymethyltransferase
(SHMT2), which is highly expressed in GBM pseudopalisading cells, plays a key
role limiting the activity of PKM2. It is thought to do so by reducing the levels of
PKM2 activators like serine, FBP, and SAICAR, facilitating survival of cells under
hypoxic conditions by limiting flux into the TCA cycle and decreasing oxygen
consumption. In a rapid xenograft model, where tumors from subcutaneously
injected cells are collected before angiogenesis, high expression levels of SHMT2
provide LN229 cells a survival advantage where the central area of the tumor
contains both viable and dying cells, however, suppression of SHMT2 or
overexpression of PKM2 reduced the survival of these cells (D. Kim et al., 2015).
3.2.6 PDK1
Pyruvate dehydrogenase kinase (PDK) is one of the enzymes that regulates the
activity of the pyruvate dehydrogenase complex (PDC). It functions by
phosphorylating one of its components (PDH), causing its inactivation and
preventing the entrance of pyruvate into the TCA cycle to be oxidized as well as
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promoting its conversion to lactate in the cytosol (Jha and Suk, 2013). As
mentioned before, transactivation of HIF1-α by PKM2 promotes increased
expression of PDK1 which supports metabolic reprogramming in GBM (Luo et al.,
2011).
In mice, with patient-derived GBM tumors, treatment with the VEGF inhibitor
bevacizumab induces hypoxia, promoting HIF1-α upregulation and increased
expression of PDK1 and other key glycolytic enzymes. Metabolic flux analysis
done using

13

C6-glucose injections in these animals show an increased glucose

flux into the tumors, higher levels of lactate and LDHA expression and a significant
reduction in many TCA metabolites like succinate, fumarate, malate, and α-KG,
indicating an uncoupling of glycolysis from oxidative phosphorylation (Fack et al.,
2015). Furthermore, transcriptomic analysis of patient-derived GSCs and GBM cell
lines U87 and U251, under short (12h) and long (7d) term severe hypoxia (0.1%
O2) showed strong upregulation of the glycolytic genes HK2, PFKP, and PDK1.
Knockdown of PFKP or PDK1 resulted in increased cell death under hypoxic
conditions but did not affect cell growth under aerobic conditions. Knockdown of
PFKP or PDK1 in GBM xenografts showed an increase in mouse survival of
+21.8% and +20,9% respectively. In vitro, GBM cells are sensitive to inhibition of
PDK1 with dichloroacetate (DCA) and this sensitivity is increased under hypoxic
conditions (Sanzey et al., 2015).
PDK1 expression is increased in GBM patient samples and correlates with EGFR
expression levels. Crosstalk between PDK1 and EGFR was observed in U251
cells and the xenograft cell line 5310, where inhibition of PDK1 with DCA reduced
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expression levels of both PDK1 and EGFR; similarly, treatment with siRNA against
PDK1 reduced levels of both total and phosphorylated EGFR. Overexpression of
EGFR in these cells showed increased cell proliferation and lactate release, which
indicates and induction of aerobic glycolysis. It should be noted, however, that
while treatment with DCA or si-PDK1 reduced cell proliferation, lactate production
and EGFR phosphorylation, it also induced apoptosis. Intracerebral injections in
mice of these cells formed tumors 60% smaller after intravenous treatment with
DCA, which resulted in reduced tumor growth and extended survival of these mice
(Velpula et al., 2013).
3.2.7 Others
Glucose-6-phosphatase complex (G6PC)
G6PC is highly expressed in GBM tumors in comparison to normal brain tissue. It
is a key regulator of the glycogenolytic pathway and glucose homeostasis, where
it provides brain tumor initiating cells (BITCs) with a growth advantage by
promoting glycogen mobilization and degradation. This is especially true under
hypoxic conditions when relying exclusively on glycolysis might not be sufficient
due to limited nutrient supply. BITCs isolated from GBM intraoperative samples
that can escape glycolytic inhibition by 2-deoxy-glucose (2DG) become highly
aggressive and more invasive when compared to control BITCs. They also showed
increased expression of G6PC, and knockdown of G6PC increased the amount of
glycogen inside the cells, and reduced these cells invasiveness and migrating
abilities (Abbadi et al., 2014).
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Glutamine Synthetase
The astrocytic enzyme glutamine synthetase (GS) catalyzes the production of
glutamine from glutamate and ammonia, and together with glutaminase (GLS), it
controls glutamine homeostasis within the cell (Rosati et al., 2013). GS is essential
to sustain proliferation of GBM cell lines undergoing glutamine starvation, where
cells increase GS expression levels upon glutamine deprivation which diminishes
their sensitivity to glutamine withdrawal. Inhibition of GS using the irreversible
inhibitor L-methionine sulfoximine (MSO) resensitizes these cells to glutamine
starvation. Under these conditions, GS maintains levels of precursors for purine
nucleotide biosynthesis, aminoimidazole-4-carboxamide ribotide (AICAR), and
inosine monophosphate (IMP). Furthermore, GS is highly expressed in GSCs
which allows these cells to grow independently of glutamine supplementation.
Patients’ samples injected with 13C6-glucose prior to surgical resection showed that
labeled glutamine was enriched in the tumor, indicating de novo synthesis in the
tumor or the adjacent tissue. These findings were confirmed by co-culturing the
GBM cell line LN18, which doesn't express GS and glutamine starvation impairs
its proliferation, and astrocytes, which enabled proliferation of LN18 under
glutamine deprivation conditions (Tardito et al., 2015). Mice with GBM orthotopic
tumors expressing GS were infused with U13-C-glutamine, showed that tumors
uptake glutamine but do not metabolize it significantly. Cells isolated from these
tumors and grown as neurospheres did not require glutamine for survival and
analysis of different metabolites after treatment with U13-C-glucose indicated that
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glutamine was produced from glucose which allows cells to avoid the requirement
for extracellular glutamine (Marin-Valencia et al., 2012b)
3.2.8 Integration of GBM metabolism
Several enzymes and signaling pathways are mutated or dysregulated in GBM,
causing changes in metabolism by altering glucose flux into the cell, promoting
aerobic glycolysis and changing pyruvate metabolism (Figure 3). Mutations in
IDH1/IDH2 have been shown to produce the oncometabolite 2-HG which is linked
to the hypermethylation phenotype of some tumors, also reduced levels of 2-KG
decrease PHD activity and HIF1-α degradation which leads to PDH
downregulation. HIF1-α increases expression of VEGF, GLUT1, LDHA, promotes
angiogenesis, invasion, and migration and contributes to maintenance and
proliferation of GSCs. EGFR overexpression or constitutive activation is a common
GBM feature which causes transcriptional activation of STAT3 and c-MYC,
increased signaling through mTORC2 and increased expression levels of PKM2,
which not only works as control point regulating glucose metabolism but also works
at the nuclear level promoting expression of c-MYC and c-MYC-dependent
glycolytic genes, and as a HIF1-α coactivator inducing expression of its target
genes. One of these genes is PDK1, which is highly expressed in GBM patients,
by inactivating PDH it diverts entrance of pyruvate to the TCA cycle promoting
glycolysis, this mechanism plays an important role in resistance to the
chemotherapeutic bevacizumab. Other enzymes provide advantages to GBM
tumors when nutrients are scarce, like G6PC allowing movement and degradation
of glycogen and GS providing precursors for de novo purine biosynthesis by

37

producing glutamine from glucose. Combined, all these changes provide GBM
tumors with different mechanisms to survive in a stressful environment deprived of
oxygen and limited nutrient access and therapies targeted to these adaptations
may improve treatment outcome and patient survival.

Figure 3. Summary of common metabolic perturbations in GBM.
Changes in expression, activation or mutations in several enzymes allow GBM
tumors to adapt and sustain tumor biology. Production of 2-HG by mutant IDH1
decreases certain TCA cycle intermediates, inhibits ATP synthase and stabilizes
HIF1-α. PKM2 diverts entrance of pyruvate into the TCA cycle and promotes
aerobic glycolysis, after EGF stimulation it translocates to the nucleus where it acts
as a coactivator of HIF1-α, thus transactivating genes that will promote glycolysis
including GLUT1 and LDHA.
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4. Mitochondria and cancer
Mitochondrial dysfunction has been associated with tumor progression of different
cancers, including brain cancers (Seoane et al., 2011; Zong et al., 2016). Most
studies focus on the role of mitochondria and the ability of a cancer cell to avoid
apoptosis, however changes in mitochondrial physiology are essential for
metabolic reprogramming (Wallace, 2012). Additionally, limited mitochondrial
dysfunction has been shown to drive cell transformation and tumorigenesis (Ichim
et al., 2015). Because mitochondria are highly integrated organelles, it is likely that
perturbations in nominal organelle function resulting from genetic polymorphisms
and a changing environment will have diverse effects within a cell.
4.1 Mitochondrial aberrations in cancer
Many cellular processes are controlled by mitochondria, such as energy
production, calcium metabolism, ROS generation, regulation of reductionoxidation (redox) status, initiation of apoptosis and contribution to different
biosynthetic pathways, functional mitochondria that display distinct adaptations to
promote sustained proliferation and survival are essential for cancer development
(Wallace, 2012).
Mitochondrial DNA (mtDNA) contains 37 genes, of these 13 encode proteins that
form part of the oxidative phosphorylation (OXPHOS) complexes, while the rest of
required proteins are nuclearly encoded (Schon et al., 2012). Functional mtDNA is
essential for cancer cells, depletion of mtDNA reduces tumor growth rates,
however, reincorporation of mtDNA is associated with tumor formation and
recovery of mitochondrial function and respiration, indicating the importance of
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mtDNA in tumor formation and progression (Tan et al., 2015). However, certain
germline mutations in the mtDNA have been associated with an increased
predisposition to certain cancers. Increased risk of invasive breast cancer or
endometrial cancer is associated with two polymorphisms in the NADH:ubiquinone
oxidoreductase core subunit 3 (ND3) gene, while mutations of cytochrome C
oxidase I (COI) gene have been linked with prostate cancer (Brandon et al., 2006).
Additionally, high levels of mtDNA mutations have been described in tumors in
comparison with normal tissue from the same patient (Chinnery et al., 2002).
Furthermore, various cancers have mutations in the nuclear encoded
mitochondrial enzymes succinate dehydrogenase (SDH), fumarate hydratase (FH)
and IDH1/IDH2 (Wallace, 2012). Inhibition of SDH leads to stabilization of HIF-1α
promoting a metabolic shift to glycolysis and increased production of mitochondrial
ROS (Chandel et al., 2000). While high levels of ROS can be toxic for the cell, in
cells where apoptosis is compromised, increased mitochondrial ROS can drive
oncogenic transformation and promote cell proliferation (F. Weinberg et al., 2010).
Mitochondria are essential for execution of apoptosis, however evasion of cell
death is a key feature of many cancers, where various cancers show an
upregulation of pro-survival B-cell lymphoma-2 (Bcl-2) proteins, which not only
promotes tumor progression but has been linked to acquired resistance to
chemotherapeutics (Giampazolias and Tait, 2016).
4.2 Bcl-2 proteins
The Bcl-2 family of proteins are master regulators of apoptosis, they are classified
into two groups pro-survival and pro-apoptotic (Moldoveanu et al., 2014). The pro-
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survival or anti-apoptotic Bcl-2 proteins contain four Bcl-2 Homology (BH) domains
(Figure 4) and are found both in the cytosol and integrated within the mitochondrial
outer membrane (MOM), the main members of the Bcl-2 anti-apoptotic group are
Bcl-2, Bcl-2-related gene, long isoform (Bcl-xL), Bcl-2-related gene A1 (A1) and
myeloid cell leukemia (Mcl-1), their main function is to prevent apoptosis by
inhibiting pro-apoptotic proteins and preserving MOM integrity (Chipuk et al.,
2010). The pro-apoptotic Bcl-2 proteins can be subdivided into two subgroups,
effectors and BH3-only proteins (Chipuk et al., 2010). Effector proteins, Bcl-2
associated X protein (BAX) and Bcl-2 antagonist killer 1 (BAK), contain BH1-3
domains (figure 4) and activation of BAK and BAX upon apoptotic stimuli promote
conformational

changes

and

oligomerization

forming

the

mitochondrial

permeability transition pore (mtPTP) initiating the mitochondrial outer membrane
permeabilization (MOMP), which effectively engages the apoptotic program
(Giampazolias and Tait, 2016; Moldoveanu et al., 2014). BH3-only proteins,
contain only the third BH domain (Figure 4), and are subdivided based on their
interactions with other Bcl-2 family proteins

by either directly activating pro-

apoptotic effector proteins or inhibiting Bcl-2 pro-survival proteins (Moldoveanu et
al., 2014). Direct activators BH3-only proteins Bcl-2 interacting domain agonist
(BID), Bcl-2 interacting mediator of cell death (BIM) and p53 modulator of
apoptosis (PUMA), are able to directly activate BAX and BAK, promoting the
conformational changes and oligomerization that will lead to pore formation and
subsequent MOMP (Chipuk and Green, 2008). The BH3-only proteins BCL-2
antagonist of cell death (BAD), BCL-2 interacting killer (BIK), BCL-2 modifying
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factor (BMF), harakiri (HRK), and Noxa, are known as desensitizers or derepressors and act by neutralizing Bcl-2 pro-survival proteins which promotes
liberation of BAX and BAK, allowing oligomerization and initiation of MOMP
(Chipuk and Green, 2008).

Figure 4. Bcl-2 family of proteins.
Pro-survival proteins have four BH domains (BH1, BH2, BH3 and BH4), proapoptotic BH3-only have only the third BH domain, and effector proteins have three
domains (BH1, BH2 and BH3).

4.3 Apoptotic priming
For cancer cells to avoid the established pathways for programmed cell death,
oncogenic programs make precise changes to the levels of Bcl-2-related family
proteins (Letai, 2008). An increase in Bcl-2 pro-survival proteins (Bcl-2, Mcl-1 and
Bcl-xL) is commonly associated with apoptotic evasion, while elevated levels of
pro-apoptotic BH3-only proteins (Bim, Bid, Puma, Noxa, etc.) may indicate proapoptotic mitochondria more susceptible to drug treatment (Letai et al., 2002;
Letai, 2008; Ryan et al., 2010; Schellenberg et al., 2013). Apoptotic priming has
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been shown to increase sensitivity of certain cancers to chemotherapy thus
improving their efficacy (Chonghaile et al., 2011; Montero et al., 2015; Vo et al.,
2012). Priming levels are determined by the replacement or sequestration of prosurvival Bcl-2 proteins by BH3-only proteins on the MOM (Chonghaile et al., 2011;
Davids et al., 2012; Reed, 2011; Vo et al., 2012). Apoptotic priming can be used
to stratify cell lines and tumor samples according to response and resistance to
chemotherapeutic drugs (Ryan and Letai, 2013).The levels of Bcl-2 proteins and
chemo-responsiveness have been evaluated in neuroblastoma, and BH3-only
levels can be used as therapeutic predictor of response and resistance (Goldsmith
et al., 2012; 2010), however the relationship between Bcl-2 protein levels and
chemo-resistance in GBM has yet to be evaluated.
4.4 Mitochondrial outer membrane permeabilization in oncogenesis and
chemosensitivity
Mitochondria plays an essential role in regulating the apoptotic pathway, in cancer
cells, evasion of apoptosis is commonly observed (Hanahan and R. A. Weinberg,
2011). Two pathways can initiate apoptosis, the extrinsic pathway which involves
activation of cell surface death receptors, and the intrinsic pathway is mediated by
mitochondria and involves initiation of MOMP, most chemotherapeutic agents act
through the intrinsic pathway (Brahmbhatt et al., 2015). Upon apoptotic stimuli,
activation of BAX and BAK by BH3-only proteins promotes oligomerization of BAX
and BAK and leads to pore formation and MOMP, mitochondrial proteins, such as
cytochrome c, second mitochondria-derived activator of caspase (SMAC) and HtrA
serine peptidase 2 (HtrA2), are released from the inter-membrane space (IMS)
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which results in caspase activation and apoptosis (Chipuk et al., 2006; Renault
and Chipuk, 2014; Tait and Green, 2013). MOMP is considered the “point of no
return”, however in some cases cells are able to survive and avoid apoptosis,
which becomes relevant in cancer and allows for tumor cell survival. In certain
types of cancer, cells can undergo incomplete MOMP leaving some intact
mitochondria, which allows them to recover and survive by bypassing caspase
activation downstream of MOMP, either due to reduced caspase activity or
expression, and it could be a potential mechanism of acquired chemoresistance
(Tait et al., 2010). Furthermore, limited MOMP after a sub-lethal stress only
sufficient to permeabilize a minority of mitochondria, may lead to caspase
activation and the subsequent cleavage of caspase substrates, promoting DNA
damage, genomic instability and tumorigenesis (Ichim et al., 2015).
5. Control of Bcl-2 protein levels
The Bcl-2 family of proteins are critical regulators of apoptosis by preserving OMM
integrity and preventing MOMP and the subsequent activation of caspases leading
to cell death, as such Bcl-2 proteins are tightly controlled both at the transcriptional
and the post-translational levels.
5.1 General
Most Bcl-2 proteins regulate their activity by heterodimerization between prosurvival and pro-apoptotic (Tsujimoto and Shimizu, 2000). BAX binds to Bcl-2 and
BAK interacts with Mcl-1 and Bcl-xL, thus preventing the conformational changes
required for BAX/BAK activation and oligomerization, however, upon apoptotic
stimuli BAX and BAK are displaced promoting cell death, when BAD
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heterodimerize with Bcl-2 and Bcl-xL and Noxa interacts with Mcl-1 (Oltvai et al.,
1993; Willis et al., 2005; E. Yang et al., 1995).
Since apoptotic control depends on the balance between levels of pro-survival and
pro-apoptotic proteins, transcriptional regulation and degradation become
instrumental in the process. The different Bcl-2 pro-survival proteins are under
distinct transcriptional programs according to their tissue specificity and their
physiological role. Mcl-1 expression is dependent on growth factors and can be
upregulated by different cytokines such as IL-3, IL-5, IL-6 GM-CSF, as well as EGF
and VEGF, and transcription is directly repressed by E2F-1 binding to the promoter
(Thomas et al., 2010). Bcl-xL transcription is also regulated by growth factors and
transcription is induced through the Janus kinase (JAK)/STAT pathway (Grad et
al., 2000). Transcription upregulation of BH3-only proteins occurs in response to
early apoptotic signals, p53 induces transcription of Noxa and Puma, while
upregulation of BIM expression occurs in response to growth factor deprivation via
FOXO3A (O forkhead box transcription factor-3A) or endoplasmic reticulum (ER)
stress by CEBP! (CCAAT-enhancer binding protein- !) or CHOP (CEBP
homologous protein) (Youle and Strasser, 2008).
Control of Bcl-2 proteins is achieved by post-translational modifications and protein
degradation, for example polyubiquitination of Mcl-1 and Bcl-2 targets them for
proteosomal degradation, while caspase-dependent cleavage of Mcl-1 occurs
during apoptosis (Neutzner et al., 2012; Thomas et al., 2010).

Furthermore,

ubiquitination and subsequent proteosomal degradation has also been observed
in the BH3-only proteins BID, BAD, BIM and BIK (Neutzner et al., 2012).
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Additionally, phosphorylation of BAD by cAMP-dependent protein kinase (PKA) or
by the 70-kDa ribosomal protein S6 kinase (p70S6K) promotes Bad inactivation by
sequestration of BAD by 14-3-3 and disrupting the binding to Bcl-2 and Bcl-xL,
which has a prosurvival effect (Harada et al., 2001; 1999; Zha et al., 1996).
5.2 MAPK
Post-translational modifications determine the fate of many Bcl-2 family proteins,
either by promoting protein stability or by working as a target for protein
degradation.

The MAPK signaling pathway controls a wide range of cellular

processes such as proliferation, differentiation, migration and death, MAPKs can
phosphorylate a large number of substrates and the outcome of signaling depends
on the magnitude, localization and set of substrates phosphorylated (Ramos,
2008). Similarly, MAPK signaling has been shown to regulate both the induction of
apoptosis as well as the inhibition, for example MEK/ERK signaling promotes
apoptosis by upregulating the expression of pro-apoptotic proteins Bak, Bax, Puma
and down regulating of Bcl-2 and Bcl-xL (Cagnol and Chambard, 2010). However,
ERK has also been associated with phosphorylation of Mcl-1 at Thr92/Thr163,
which promotes Mcl-1 stability and improves anti-apoptotic function (Domina et al.,
2004; Thomas et al., 2010), and phosphorylation of Bim which targets it for
ubiquitination and subsequent proteosomal degradation, it also prevents Bim from
interacting and activating Bax, which prevents pore formation and has an
antiapoptotic effect (Ley et al., 2005).
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5.3 JNK and Sab
JNK signaling has been linked to induction of apoptosis and chemosensitization in
neuroblastoma cells (Cheng et al., 2014; Fey et al., 2015; Filomeni et al., 2003;
Waetzig et al., 2009). Upon different stress stimuli, phosphorylated JNK
translocates to the mitochondria where it interacts with the c-terminal part of Sab
through a kinase interaction motif (KIM) (Wiltshire et al., 2004; 2002). At the
mitochondria, stress-induced JNK signaling promotes mitochondrial dysfunction
by amplifying reactive oxygen species (ROS) production, inducing mitochondrial
permeability and impairing bioenergetics (J. W. Chambers and LoGrasso, 2011;
Hanawa et al., 2008). Mitochondrial JNK signaling also plays a role in cell death,
where activated JNK phosphorylates members of the Bcl-2 family of proteins thus
promoting apoptosis (J. W. Chambers et al., 2011; Schroeter et al., 2003). JNK
phosphorylates Bcl-2 at Ser70 inactivating the protein and facilitating apoptosis,
also phosphorylation of Mcl-1 is the first step for Mcl-1 stress-induced degradation
(Morel et al., 2009; Yamamoto et al., 1999). Furthermore, JNK-mediated
phosphorylation of pro-apoptotic proteins Bim and Bmf, promotes their release
from motor complexes where they remain sequestered in the cytosol, once
released they are able to induce apoptosis via Bax (Lei and Davis, 2003).
6. Sab
Sab, also known as SH3BP5, is an outer mitochondrial membrane protein that acts
as a scaffold for the c-Jun N-Terminal Kinase (JNK) (Wiltshire et al., 2002).
Inhibition of the JNK-Sab interaction prevents oxidative stress, mitochondrial
dysfunction and cell death. Furthermore amplification of JNK/Sab-mediated
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signaling has been shown to sensitize cancer cells and improve chemotherapeutic
efficacy (J. W. Chambers et al., 2011; 2013a; 2013b; T. P. Chambers et al., 2015;
Wiltshire et al., 2004). However, the impact of Sab-mediated signaling on
mitochondrial function and apoptosis has yet to be fully delineated in human
glioblastoma or neuroblastoma.
6.1 Structure
Sab was identified using a protein-protein interaction screen by its ability to bind
Bruton’s tyrosine kinase (BTK) through the SH3 (Src homology 3) domain
(Wiltshire et al., 2002). Further inspection of the Sab sequence determine the
presence of two KIM motifs, KIM1 and KIM2, in C-terminal portion of the protein,
which are required for JNK binding (Wiltshire et al., 2004; 2002). Additionally,
bioinformatics studies of the full-length Sab revealed the presence of another two
prospective protein-protein interaction motifs (Figure 5). The N-terminal portion of
the protein contains two coiled-coiled (CC) motifs, which are generally associated
with dimerization and interaction with other proteins (Strauss and S. Keller, 2008),
the SH3 motif located within CC2.

Figure 5. Schematic representation of Sab
CC1: coiled-coiled motif 1, CC2: coiled-coiled motif 2, TM transmembrane domain,
KIM1: kinase interaction motif 1, KIM2: kinase interaction motif 2, S:
phosphorylation sites.
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6.2 Functions
Sab functions as an OMM scaffold for JNK (Wiltshire et al., 2002). Interaction
between Sab and JNK is required for the mitochondrial effects of JNK signaling
without impairing JNK nuclear signaling, as demonstrated by inhibition of this
interaction using Tat-SabKIM1 peptide, which prevented Bcl-2 phosphorylation, loss
of mitochondrial membrane potential and cell death but had no effect on c-Jun
phosphorylation or transcription of AP-1 (J. W. Chambers et al., 2011). Inhibition
of mitochondrial JNK signaling by either silencing Sab or using Tat-SabKIM1
peptide, has a protective effect in sustained liver injury and hepatotoxicity models
and in the 6-hydroxydopamine neurotoxicity model (J. W. Chambers et al., 2013a;
Win et al., 2011). Moreover, interaction of JNK with Sab has been shown to inhibit
mitochondrial respiration, increases production of ROS, which leads to cell death
in a model of hepatocyte lipotoxicity (Win et al., 2015) and ER stress induced by
tunicamycin or brefeldin A (BFA) (Win et al., 2014). Additionally, Sab mediates
oxidative stress and decreases mitochondrial respiration, ATP production and
membrane potential in cardiomyocyte-like cells after treatment with imatinib (T. P.
Chambers et al., 2017). Sab as also been shown to be expressed throughput the
brain, and inhibition of Sab using the Tat-SabKIM1 peptide altered activity of cultured
hippocampal neurons by decreasing the firing frequency and the amplitude of
spikes, indicating that Sab- mediated signaling plays a role in normal neuronal
function (Sodero et al., 2017).
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1. Problem Statement
Malignancies of the central nervous system often have poor prognoses due to the
rapid recurrence of resistant disease following aggressive treatments. For
example, glioblastoma (GBM) patients have a mean life expectancy of 15 months.
An examination of the literature revealed that the mechanisms of cell death
evasion in CNS tumors has not been rigorously explored. By characterizing the
apoptosis machinery and related signal transduction pathways, we will be able to
fill this knowledge gap and use the expected outcomes of our research to develop
therapeutic approaches to fully enable cell death signaling in CNS tumor cells.
Because many of the cell death responses converge on mitochondria, it is
necessary to determine how these crucial organelles are altered from the process
of oncogenesis. Changes in mitochondrial metabolism and signal transduction in
cancer have been shown to aid in tumor proliferation, metastasis, and resistance.
Thus, there is an urgent need to characterize changes in CNS tumor mitochondria
to develop effective treatments to extend the quality of lives for patients.
2. Hypothesis and rationale
Dysregulation of cellular control of mitochondria is an emerging component of
oncogenesis in brain tumors (Ichim et al., 2015; Seoane et al., 2011). Restoring
proper regulation of mitochondrial physiology may be a useful therapeutic
approach to impair tumor progression and sensitize tumor cells to therapies.
Diminished apoptosis is a hallmark of numerous cancers, including central nervous
system (CNS) tumors like neuroblastoma and glioblastoma (GBM) (Hanahan and
Weinberg, 2011). Increased levels of pro-survival Bcl-2 proteins (Bcl-2, Mcl-1, and
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Bcl-xL) are associated with decreased apoptosis, while elevated levels of BH3only proteins (Bim, Bid, Puma, Noxa, etc.) are characteristic of pro-apoptotic
mitochondria susceptible to chemotherapy (Brunelle and Letai, 2009; Certo et al.,
2006; Chonghaile et al., 2011; Letai et al., 2002). In neuroblastoma, levels of Bcl2 and BH3-only can be used to predict chemotherapeutic response (Goldsmith et
al., 2012). In GBM, the relationship between Bcl-2 protein levels and chemoresistance has yet to be rigorously evaluated.
The molecular mechanisms responsible for controlling Bcl-2 protein abundance on
mitochondria in both neuroblastoma and GBM has yet to be fully delineated. The
c-Jun N-terminal kinase (JNK) can induce apoptotic signaling through the
manipulation of Bcl-2 proteins. Stress-induced activation of JNK induces
translocation of the kinase to mitochondria initiating a signaling cascade that
culminates in mitochondrial dysfunction and apoptosis (J. W. Chambers et al.,
2011). At mitochondria, JNK interacts with the scaffold protein Sab, and inhibition
of the JNK-Sab interaction prevents oxidative stress, mitochondrial dysfunction
and cell death (J. W. Chambers and LoGrasso, 2011). Furthermore amplification
of JNK/Sab-mediated signaling has been shown to sensitize cancer cells and
improve chemotherapeutic efficacy (J. W. Chambers et al., 2011; 2013a; 2013b;
T. P. Chambers et al., 2015).
Intriguingly, our preliminary studies investigating the relationship between Sab
expression and therapeutic efficacy in ten GBM cell lines revealed the presence of
a novel Sab splice variant that lacks the original mitochondrial localization signal.
The splice variant of Sab has not been characterized, and thus its impact on GBM
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physiology is still unknown. Therefore, there is a critical need to understand the
effects of Sab, the Sab variant and JNK signaling in neuroblastoma and GBM
physiology. Failure to delineate the impact of Sab-mediated signaling on GBM and
neuroblastoma physiology and chemo-responsiveness will obstruct the search for
efficacious therapeutic approaches and prevent the proper treatment of patients.
The long-term goal of our research is to understand the regulation of mitochondrial
JNK signaling in CNS tumor resistance. Our research objective is to determine
how Sab-mediated JNK signaling influences cell death responses GBM and CNSbased neuroblastoma. Our central hypothesis is that Sab-mediated signaling
promotes stress-induced mitochondrial dysfunction and apoptosis, whereas the
diminished Sab levels may lead to reduced apoptotic potential. This hypothesis
was formulated based on our published (J. W. Chambers et al., 2011; T. P.
Chambers et al., 2015) and preliminary data demonstrating that Sab levels
influence chemoresponsiveness in gynecological cancers. The rationale for our
proposed research is that understanding the role of mitochondrial JNK signaling in
CNS tumor biology will provide insights into oncogenicity and chemoresponsiveness.
3. Project Aims
To investigate our hypothesis and accomplish our research objective, we propose
the following specific aims.
1. Examine mitochondrial physiology characteristics of GBM-derived cell lines and
determine its impact on apoptosis and chemoresistance. Increased levels of prosurvival Bcl-2 proteins (Bcl-2, Mcl-1, and Bcl-xL) are associated with decreased
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apoptosis, while elevated levels of BH3-only proteins (Bim, Bid, Puma, Noxa, etc.)
are characteristic of pro-apoptotic mitochondria susceptible to treatment (Brunelle
and Letai, 2009; Certo et al., 2006; Chonghaile et al., 2011; Letai et al., 2002).
Apoptotic priming, which determines the ratio between Bcl-2 proteins and BH3only proteins, can be used to predict chemotherapeutic response and resistance
in other cancers, however the capability to use as a biomarker in GBM has not
been studied. The potential contribution of Sab-mediated signaling in GBM chemoresponse is unknown. For this aim, our working hypothesis is that Bcl-2/BH3-only
protein levels correlate with chemoresponsiveness in GBM, which also correlates
with Sab expression levels. We will determine the expression levels of Bcl-2
proteins, BH3-only proteins and Sab, and how they correlate to cell viability and
apoptosis after treatment with chemotherapeutic reagents.
2. Define the cellular distribution of the GBM Sab splice variant and determine its
impact on JNK-induced mitochondrial dysfunction and apoptosis. Mitochondrial
JNK signaling promotes oxidative stress, mitochondrial dysfunction and initiates
apoptosis. Peptide mimicry of the Sab-JNK interaction prevents mitochondrial
dysfunction (J. W. Chambers et al., 2011). Sab is located in the outer mitochondrial
membrane (Wiltshire et al., 2002); however, the localization of the Sab variant is
unknown. For this aim, our working hypothesis is that the Sab variant has a
different cellular localization than Sab, because preliminary data suggest it has lost
the original mitochondrial localization signal, and due to its distinct distribution, the
Sab variant inhibits apoptotic priming and alters the magnitude of stress-induced
mitochondrial dysfunction. We will determine the cellular location of the Sab
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variant. Furthermore, we will survey JNK signaling and measure mitochondrial
health in order to determine the extent of dysfunction in GBM cells expressing the
Sab variant.
3. Determine the impact of Sab-mediated signaling on mitochondrial function and
apoptosis in human Neuroblastoma cell lines. Blocking mitochondrial JNK
signaling affects Bcl-2 levels and decreases apoptosis in neuroblastoma cells,
while amplification of Sab-mediated JNK signaling has been shown to sensitize
cancer cells to chemotherapeutic treatment (J. W. Chambers et al., 2013b; 2013a;
2011; T. P. Chambers et al., 2015; Matthay et al., 2009). For this aim, our working
hypothesis is that expression levels of Sab in neuroblastoma cells correlate with
chemo-sensitivity. Preliminary data suggests that Sab expression is reduced in
neuroblastoma patients which alters the cells metabolic phenotype and their
chemoresponsiveness. We will determine the impact of Sab-mediated signaling
on mitochondrial metabolism, and glycolysis, as well as cell proliferation and
apoptosis.
4. Abstract of the project
As a result of this project, we have prepared three manuscripts for submission,
which will include chapters 3, 4 and 5 of this dissertation. The abstracts of these
chapters appear below.
Chapter 3 - Bcl-2 Profiling Defines the Therapeutic Responsiveness in
Continuous Glioblastoma Cultures.
Glioblastoma (GBM), is the most common primary brain tumors and have the
highest mortality among older adults. The therapeutic standard for managing GBM

77

remains a combination of surgery, chemotherapy (temozolomide – TMZ), and
radiotherapy; however, there is no cure, nor has there been any significant
advancement in the clinical approach to GBM since this protocol was established
in 2005. This study aims to better understand the molecular characteristics of
GBM-derived cell lines to better define treatment groups and potentially identify
new avenues for therapy. This study utilized ten continuous GBM cell lines and
examined the concentrations of Bcl-2 family proteins on mitochondria for each of
the cell lines. The measures were correlated to IC50 values for TMZ. We assessed
cellular viability in the presence of increasing doses of TMZ (0-10mM) for each cell
line. Western blot analysis of pro-survival and pro-apoptotic Bcl-2 proteins
revealed that Bcl-2 levels corresponded to chemo-sensitivity, while increased
levels of Bim promoted chemo-sensitivity in GBM cell lines. The ratio of Bcl-2 and
Bim expression was found to be significantly correlated (p<0.0001) to TMZ
responsiveness (r = 0.9755). Induction of TMZ resistance in U87 cell by exposure
to a hypoxic environment increased the Bcl-2/Bim ratio. We found that Bcl-2
protein profiling, specifically the Bcl-2/Bim ratio, was a useful means to determine
therapeutic response and resistance to TMZ.
Chapter 4 - A novel splice variant of Sab alters mitochondrial physiology
Mitochondria-cell communication is required for optimal cell function and to monitor
mitochondrial health status. Ultimately, mitochondria-cell circuits produce and
receive signals that influence biological outcomes. However, the precise molecular
mechanisms responsible for mitochondria-cell communication are not very well
understood. Scaffold proteins on the mitochondria outer membrane (MOM)
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represent crucial hubs for mitochondria-cell communication, where the relative
abundance of discrete scaffold proteins will influence the magnitude of a distinct
signal transduction event and determine the local biological outcome.
Furthermore, variation in scaffold proteins may diversify signaling modules or even
polarize mitochondria-cell communication towards specific biological outcomes.
The MOM scaffold protein Sab facilitates mitogen-activated protein kinases
(MAPKs) signaling on mitochondria which affects organelle function and cell
viability. Our previous work demonstrates that Sab levels influence cellular
sensitivity to chemotherapy agents in gynecological cancer cell lines. While
screening glioma cell lines for Sab protein concentrations, we discovered a unique
variant of Sab with an N-terminal truncation that deletes the original mitochondrial
localization sequence and a coiled-coil motif. Thus, the goal of our current project
is to biochemically characterize the Sab variant, distinguish the function of the
truncated Sab variant from that of full-length Sab, and determine the impact of
variant-mediated signal transduction on mitochondrial function. We cloned human
SF268 cells and found clones that expressed full-length Sab alone and those that
expressed both the full length and the variant. We then characterized the cellular
morphology, growth rate, respiration and drug responsiveness. We found that the
truncated Sab variant localizes to mitochondria, which could be attributed to a new
N-terminal stretch of cationic amino acids. Cells that express the variant display
an increased growth rate compared to cells with only full-length Sab. Truncated
Sab expressing cells have a large, round morphology, while cells that do not
express the variant have a fibroblast-like morphology. Expression of the variant
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promotes a metabolic shift from respiration to a more glycolysis-dependent
phenotype. The truncated Sab variant affects the cellular response to stress, as
cells that lack the variant are less sensitive to both genotoxic stress and
mitochondrial stress. Our work illustrates that Sab variants may have distinct
effects on mitochondrial function. Moreover, altering the structures and
concentrations of MOM scaffold proteins represents a unique approach to
manipulate organelle function and disease pathophysiology.
Chapter 5 - Sab-mediated signaling influences metabolism and
chemosusceptibility in human neuroblastoma cells
Late stage neuroblastomas are commonly resistant to conventional treatments,
including chemotherapy, and most patients experience transient effects of
chemotherapy followed by a recurrence with a highly malignant treatment-resistant
form of neuroblastoma. Thus, new therapeutic options are needed to treat late
stage neuroblastomas. Our recent studies in cancer have demonstrated that
mitochondrial c-Jun N-terminal kinase (JNK) signaling on the outer mitochondrial
scaffold protein Sab is an essential component of cell death responses.
Consequently, we found that Sab expression is down-regulated in neuroblastoma
patients. In our current study, we examined the impact of Sab-mediated signaling
on neuroblastoma physiology. Inhibition Sab-mediated signaling altered cellular
metabolism in SH-SY5Y cells as determined by analyses. Treatment of SH-SY5Y
cells with the Tat-SabKIM1 peptide, a peptide known to inhibit JNK signaling on Sab,
increased oxidation of both glucose and glutamine while decreasing the glycolytic
rate. The change in glycolytic rate was not due to a change in glycolytic gene
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expression. Furthermore, the SH-SY5Y mitochondria treated with the Tat-SabKIM1
peptide had more Bcl-2 (pro-survival) and less Bim (pro-apoptotic) when compared
to controls. SH-SY5Y cells treated with the inhibitory Sab peptide also had reduced
proliferation rates and were resistant to chemotherapy agents (carboplatin,
cyclophosphamide, doxorubicin, etoposide, and vincristine). Over-expression of
Sab in neuroblastoma cells reversed the effects of Sab inhibition. Finally,
examination of additional neuroblastoma cell lines revealed that Sab levels
correspond to proliferation rate, metabolic phenotype, and chemosensitivity.
Consequently, we propose that Sab levels represent a new prognostic for
therapeutic efficacy in neuroblastoma patients.
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CHAPTER III
Bcl-2 Profiling Defines the Therapeutic Responsiveness in Continuous
Glioblastoma Cultures.
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1. Introduction
Grade IV astrocytoma, also known as glioblastoma multiforme (GBM), are the
most common and aggressive type of primary brain tumors in adults (Wen and
Kesari, 2008). GBM accounts for about 17% of brain cancers in adults between 45
and 70 years of age, affecting more predominantly males than females (Furnari et
al., 2007). Patients diagnosed with GBM have a poor prognosis, the median
survival is 14.6 month, two-year survival is less than 30% and five-year survival is
less than 10% (Furnari et al., 2007; Wen and Kesari, 2008). The standard of care
for the disease, a combination of surgery, chemotherapy (temozolomide (TMZ)),
and radiation, is ineffective and the response to TMZ varies greatly between
patients (Robins et al., 2007; Stupp et al., 2005). New diagnostic strategies are
required to better stratify patients in order to define an appropriate and effective
treatment plan.
Resistance to cell death is a hallmark of cancers, including GBM (Hanahan and
Weinberg, 2011). Circumventing the established circuitry for programmed cell
death involves precise manipulation of the Bcl-2 protein family (Letai, 2008).
Apoptotic evasion is commonly associated with increasing pro-survival Bcl-2
proteins (Bcl-2, Mcl-1, and Bcl-xL), while elevated pro-apoptotic BH3-only proteins
(Bim, Bid, Puma, Noxa, etc.) indicate that cancer cells may be susceptible to
treatments (Letai et al., 2002; Letai, 2008; Ryan et al., 2010; Schellenberg et al.,
2013). Apoptotic priming, which is dependent on the replacement or sequestration
of pro-survival Bcl-2 proteins by BH3-only proteins on the mitochondrial outer
membrane, has been shown to increase the sensitivity of certain cancers and solid
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tumors to chemotherapy improving its efficacy (Chonghaile et al., 2011; Davids et
al., 2012; Reed, 2011; Vo et al., 2012). Moreover, apoptotic priming has been used
to stratify cell lines and tumor samples according to chemotherapeutic responses
and resistance (Ryan and Letai, 2013). While the levels of Bcl-2 proteins and
chemo-responsiveness in solid tumors has been well evaluated in recent studies,
the relationship between Bcl-2 protein levels and chemo-resistance in GBM has
yet to be evaluated.
In our current study, we examined the mitochondrial characteristics, specifically
Bcl-2 profiling, of ten (10) established GBM cell lines in order to address how the
concentrations of these proteins correlate to TMZ sensitivity. Our Bcl-2 profiling of
10 GBM cells lines reveal a diverse set of expression profiles for the proteins of
the Bcl-2 family. We found expression trends for two proteins Bcl-2 (pro-survival)
and Bim (pro-apoptosis). Cells that were resistant to TMZ (U118, SNB19, and
U251) had the highest levels of BCl-2 expression and the lowest concentrations of
Bim; meanwhile, cells sensitive to TMZ (H4 and SNB75) had the lowest levels of
Bcl-2 and the highest levels of Bim. Spearman correlation found that the Bcl-2/Bim
ratio in the 10 cell lines were highly related (r = 0.9755, p<0.0001). These
preliminary data suggest that Bcl-2 protein plays a critical role in the effectiveness
of chemotherapy in individual cell lines and that mitochondria may be a useful
target for complementary therapies for GBM treatment.
2. Materials and Methods
Materials: GBM cell lines, A-172 (CRL-1620), H4 (HTB-148), U-87 MG (HTB-14),
and U-118 MG (HTB-15), were purchased from American Type Culture Collection
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(Manassas, VA). The remaining GBM cell lines were obtained through the National
Institutes of Cancer (NCI) from the NCI-60 cell panel. Cell culture media was
purchased from Invitrogen (Grand Island, NY), and serum was purchased from
Denville Scientific (South Plainfield, NJ). General chemicals were purchased from
Fisher Scientific (Pittsburgh, PA) and Sigma Aldrich (St. Louis, MO) as indicated
below. Unless indicated below, antibodies were purchased from Cell Signaling
Technology (Danvers, MA).
Cell Culture: GBM cell lines were grown under normal cell culture conditions (37oC
and 5% CO2 with humidity). A-172, H4, U-87 MG, U-118 MG cells and the cells
from the NCI-60 panel (SF-268, SF-295, SF-539, SNB-19, SNB-75 and U-251)
were grown in Dulbucco’s Modified Essential Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1,000 U/mL penicillin, 100µg/mL streptomycin, and
5µg/mL plasmocin. Primary fetal human astrocytes (Sciencell Direct) were
obtained and grown in astrocyte-specific media (Sciencell Direct) under normal cell
culture conditions.
Determining Cell-based IC50s for Temozolomide (TMZ): To determine the relative
chemo-sensitivity of the GBM cell lines, cells were treated with increasing
concentrations of TMZ (0-10mM). Briefly, GBM cells were plated at 5x103 cells per
well in black-walled, clear bottom plates (Perkin Elmer) and grown overnight. The
cells were then treated with chemotherapeutic agents for 48 hours. The cells were
washed three times in PBS and fixed in 4% paraformaldehyde/PBS. The cells were
then stained with 5µM TO-PRO-3 for 45 minutes at RT. The cells were then
washed three times in Hank’s Buffered Saline Solution (HBSS). The plate was
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imaged using the Odyssey CLx scanner (Licor Biosciences) and analyzed using
the Image Studio 2.0 software (Licor Biosciences). The IC50 for each cell line was
calculated using the GraphPad Prism7© software.
Cell Lysis and Western Blot Analysis: To isolate proteins from cells for analysis,
cells were plated at 2.5x105 cells/well in a six well plate unless otherwise indicated.
Following treatment, cells were lysed, and proteins were harvested as previously
described. Briefly, cells were washed twice in phosphate buffered saline (PBS;
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4) and lysed in
radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH 8.0, 150mM
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 1mM
phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase
Inhibitor Cocktails (Thermo Scientific). Cells were incubated while gently rocking
at 4°C for five minutes, and then transferred to a sterile micro-centrifuge tube. After
two minutes on ice, cell disruption was completed using sonication. The lysate was
cleared by centrifugation at 14,000 × g for 15 minutes. Protein concentrations of
the supernatant were measured using the Pierce BCA Assay kit according to
manufacturer’s directions. Proteins were then resolved by SDS-PAGE and
transferred onto low fluorescence PVDF membranes. Membranes were placed in
blocking buffer comprised of PBS supplemented with either 5% non-fat milk (for
standard blots) or 5% bovine serum albumin (BSA; for phosphor-specific blots) and
incubated for at least one hour at room temperature (RT) or overnight at 4°C. The
membranes were incubated in PBS containing 0.1% Tween 20 (PBST) and either
5% non-fat milk or BSA in the presence of primary antibodies for at least 2.5 hours
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(RT) or overnight (4oC) while gently rocking. Primary antibodies specific for Bcl-2
(CST, 2870), Bcl-xL (CST, 2764), Mcl-1 (CST, 5453), Bad (CST, 9239), Bik (CST,
4592), Bim (CST, 2933), Bid (CST, 2002), PUMA (CST, 12450), Bax (CST, 5023),
Bak (CST, 12105), Actin (CST, 4970),and α-tubulin (CST, 2144) were used at
dilutions of 1:1000 for these studies. Membranes were washed three times for five
minutes in PBST. Membranes were incubated with secondary antibodies in the
appropriate blocking buffer at a ratio of 1:20,000 for one hour at RT gently rocking.
The following secondary antibodies were used in the experiments below: IRDye
680RD Goat anti-Rabbit (926-32211) and IRDye 800CW Goat anti-Mouse (92668070) (Licor Biosciences). Membranes were again washed three times for five
minutes in PBST. Membranes were analyzed using fluorescence detection using
the Odyssey CLx near infrared scanner (Licor Biosciences). The corresponding
bands on the western blots were quantified and normalized using the Image Studio
2.0 software (Licor Biosciences). The fluorescence of specific bands of interest
were divided by the fluorescence of the loading control band to equilibrate signal
strength and loading. The resulting signal was then normalized by dividing the
signals from treated samples by respective untreated or normal tissue control
signals for each experiment.
In vitro Hypoxic Cycling of U-87 MG cells: U-87 MG cells were grown as indicated
above under normal cell culture conditions. The cells were then placed in a
Heracell 150i incubator (Thermo Scientific) and nitrogen gas was used to create a
hypoxic environment of 1% O2. The U-87 MG cells were then placed in the hypoxic
environment for one (1) hour, and then returned to a normoxic environment for 30
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minutes. This exchange was repeated for two (2) additional cycles. For noninterrupted hypoxia experiments, U-87 MG cells were place in a 1% O2
environment for four (4) hours prior to analysis. Hypoxic adaptation was confirmed
by increased hypoxia-inducible factor 1a (HIF-1a) using western blot analysis.
Sensitization the BH3-mimetic ABT-737: ABT-737 is a well-established BH3mimetic that targets Bcl-2 and Bcl-xL and can induce apoptosis in a Bax/Bak
dependent manner.
Inhibition of Mcl-1: S63845 is a Mcl-1 inhibitor known to selectively induce
apoptosis in Mcl-1-dependent cancers.
Cytotoxicity Assays: To measure the extent of cell death induced during hypoxic
cycling, ABT-737, and S63845 sensitization, we employed three distinct assays.
First, we utilized TO-PRO-3 staining for cell viability as described above. Next, we
determined caspase activity, cells were grown on 6-well plates. After treatment,
cells were lysed with 100µL of PBS supplemented with 1% TritonX-100, for 5
minutes on ice. Cell disruption was completed by sonication, and samples were
centrifuged at 15,000 x g for 10 minutes at 4oC. Then, 25µL of the lysate was
transferred to a black 96-well plate and incubated with 200µL of the substrate
solution comprised of PBS, with or without 25µg/ml of caspase substrate AcDEVD-AMC (37µM) in PBS supplemented with 5mM DTT. The assay was
incubated at 37oC for 30 minutes, and fluorescence was measured (excitation:
380nm; emission: 440nm).
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Biological Replicates and Statistics: A minimum of four biological replicates were
used for cell-based studies, with a minimum of six experimental replicates. To
evaluate differences between sample groups, the Mann-Whitney test was used.
Experiments with more than three comparison groups were subjected analysis of
variance (ANOVA) followed by the Tukey Honest Difference test to compare
means. Correlation statistics were performed using the Spearman nonparametric
test. An asterisk in figures indicated p value is less than 0.05. For correlation
between GBM cell lines, standard calculations for the correlation coefficient (r) and
r2 were performed. Data are displayed as means with error bars representing plus
and minus one standard deviation of the mean.
3. Results
3.1 GBM cell lines have distinct sensitivities to TMZ. To determine the chemoresponsiveness of the GBM cell lines, the acquired cell panel was grown in 96-well
plates and treated with increasing concentrations of TMZ (0-10mM) for 72 hours;
afterwards, the cells were fixed and stained with TO-PRO-3 to determine the
number of cells remaining (Figure 6A). The IC50s for each cell line were determined
by plotting the fluorescence of the remaining cells against the concentration of TMZ
(Figure 6B). Using non-parametric analysis of these data, the IC50s were calculated
from four biological replicates (Table 4). Based on these experiments, we found
that three cell lines (U118, SNB19, and U251) were unresponsive (i.e. resistant)
to TMZ at supraphysiological concentrations up to 10mM, while the remaining
seven cell lines had varying degrees of responsiveness with H4 and SNB75 cells
being the most sensitive of the cell lines. Since MGMT promoter methylation has
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been previously used as prognostic marker, we decided to evaluate if MGMT
protein expression levels were related to TMZ chemo-responsiveness, but we did
not observe any correlation between the two (Figure S1). We further investigated
if chemo-responsiveness was related to metabolic differences between the cell
lines we first examined expression levels of glycolytic proteins, however there was
no discernable trend in the expression of the metabolic enzymes (HKI, HK2,
PKM1/2, LDHA, MCT1, MCT4) analyzed (Figure S2). We also examined if the
differences observed in response to TMZ was related to a metabolic shift, usually
observed in cancer, we measured mitochondrial respiration and glycolysis in the
presence or absence of glucose and glutamine, similarly we couldn't determine a
consistent trend between metabolic status and chemo-responsiveness (Figure
S3).

Figure 6. Determining IC50 values for TMZ in GBM Cell Lines.
(A) GBM cell lines were incubated for 72 hours in the presence of 0-10mM TMZ.
The cells were then fixed and stained with TO-PRO-3 to determine the number of
cells. Displayed in this figure are the TMZ-sensitive line (H4) and the TMZ-resistant
line (U118). (B) The fluorescence for each TMZ dose was plotted (n=4) and the
IC50 value was calculated using GraphPad® Prism and displayed in Table 4. Here
we display prototypic plots for A172, H4, U118, and U87MG cells.
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Table 4: TMZ IC50 Values for Established GBM cell Lines
Cell Line

TMZ IC50 (mM)

U118

>10 mM†

SNB19

>10 mM†

U251

>10 mM†

U87

0.75 ± 0.11

SF295

0.64 ± 0.08

SF539

0.37 ± 0.03

SF268

0.21 ± 0.10

A172

0.18 ± 0.05

SNB75

0.07 ± 0.02

H4

0.04 ± 0.01

IC50 values for GBM cell lines were determined in a 96-well format on 5x103
cells/well using cell-based fluorescence. †The dose curve for this experiment was
from 0-10mM due to the solubility of TMZ
3.2 Bcl-2 protein levels are distinct among GBM cell lines. To evaluate if the
chemo-responsiveness of the 10 cell lines was related to the levels of Bcl-2 family
proteins, we examined the expression pro-survival and pro-apoptotic proteins
across the panel. Examination of the pro-survival Bcl-2 proteins revealed that Bcl2 levels were highest in U-118 MG, SNB-19, and U-251 cell lines, five cell lines (U87 MG, SF-295, SF-539, SF-268, and A-172) had some expression of Bcl-2, and
two cell lines, H4 and SNB-75, had no detectable Bcl-2 expression (Figure 7).
Conversely, no discernable trend could be found for other pro-survival Bcl-2
proteins, Bcl-xL or Mcl-1 (Figure 7, Figure S4). Next, we examined the expression
of pro-apoptotic, BH3-only members of the Bcl-2 family. Bim displayed a
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complementary expression pattern to Bcl-2 in the cell lines. U-118 MG, SNB-19,
and U251 had no or very low expression of Bim, while U-87 MG, SF-295, SF-539,
SF-268, and A-172 had higher levels of Bim (Figure 7). H4 and SNB-75 had the
highest levels of Bim expression among the cell lines across three biological
replicates (Figure 7). There was no discernable trend in the expression of other
BH3-only proteins (Bad, Bid, Bik, PUMA) analyzed (Figure S4). Actin served as a
loading control for all experiments.

Figure 7. Bcl-2 profiling of GBM Cell Lines.
GBM cell lines were grown, lysed, and protein levels were assessed by western
blot analysis for Bcl-2 family proteins. Expression was normalized to the actin
loading control. (A) Representative western blot (n=3). Quantification of
normalized protein expression of (B) Bcl-2, (C) Mcl-1 and (D) Bim. One-way
ANOVA was used to determine differences in protein expression between cell
lines, p<0.05. Bcl-2 protein level was significantly different in U118 cells, asterisk
represent different levels of significance ** p<0.002, *** p<0.0005
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3.3 The Bcl-2/Bim Ratio Correlates to Chemo-responsiveness. To determine
if the expression of Bcl-2 and Bim levels corresponded to chemo-resistance in
GBM cell lines, we divided the relative expression of Bcl-2 by that of Bim. This ratio
provides the amount of pro-survival capacity within mitochondria. A high ratio
indicates a great survival capacity (i.e. resistance), while a low value would indicate
sensitivity to stress. The ratio was calculated for each cell line and plotted against
the previously calculated IC50s for TMZ. We used a non-parametric correlation test
(Spearman method) to determine the correlation coefficient (r) (Figure 8). Analysis
of the Bcl-2/Bim ratio and TMZ IC50s provided an r value of 0.9755 (p<0.0001)
suggesting a significant relationship could exist between these two measures
(Figure 8). Further, we used these values to stratify the cells by chemoresponsiveness. Cells with a high Bcl-2/Bim were chemo-resistant (U-118 MG,
SNB-19, and U-251), those with a moderate Bcl-2/Bim value were responsive at
higher concentrations of TMZ (U-87 MG, SF-295, SF539, SF268, and A172), and
those cells with a very low Bcl-2/Bim (H4 and SNB75) were found to be sensitive
to TMZ.
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Figure 8. Correlation of Bcl-2/Bim to TMZ Sensitivity.
The Bcl-2/Bim ratio was calculated for each of the GBM cell lines and plotted
against the corresponding IC50 for TMZ (n=4). Spearman correlation test was
used to determine the correlation coefficient (r).
3.4 Inducing resistance increases the Bcl-2/Bim ratio. It has been previously
shown that hypoxic cycling can induce chemo-resistance in U-87 MG cells. To
determine if this had an impact on the Bcl-2/Bim ratio, we incubated U-87 MG cells
under normoxic and hypoxic conditions for 16 hours. We then tested the cells
response to TMZ and found that hypoxic cells had a five-fold increase in the IC50
for TMZ (Figure 9A). Analysis of Bcl-2 and Bim levels indicate that Bcl-2 levels
increased during the hypoxic treatment of U-87 MG cells, while Bim levels
decreased (Figure 9B). Mitochondrial concentration in U-87 MG cells remained the
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same as indicated by western blot detection of cyclo-oxygenase IV (COX-1V) and
Tubulin was used as a loading control (Figure 9B). This suggests that the Bcl2/Bim ratio is a useful assessment of TMZ-responsiveness.

Figure 9: Inducing TMZ Resistance in U87 Cells Increases Bcl-2/Bim Ratio.
U87MG cells were plated in 35-mm cell culture dishes and exposed to either
normoxia or hypoxia for 16 hours. After 16 hour, cells were either treated with (A)
TMZ to determine the IC50 for each condition or (B) lysed in order to measure the
levels of HIF-1a, Bcl-2 and Bim. COX-IV was used as a mitochondrial loading
control, while Tubulin was used as a cellular loading control. The Bcl-2/Bim ratio
was calculated by dividing the normalized expression levels of Bcl-2 and Bim.
3.5 Inhibition of both Bcl-2 and Mcl-1 is necessary to improve chemoresponsiveness. Since the Bcl-2/Bim ratio correlates to chemo-responsiveness,
and inducing resistance increases the ratio, we evaluated if inhibition of Bcl-2 by
ABT-737,

a

BH3

mimetic

that

inhibits

Bcl-2

and

Bcl-xL

enhanced

chemoresponsiveness, however concurrent treatment of ABT-737 and TMZ only
modestly improved the efficacy of TMZ (Figure S5). We further investigated if
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inhibition of Mcl-1 was also required to induce cell death, after 72 hours treatment
with increasing concentrations of ABT-737, S63845 (Mcl-1 inhibitor) or a
combination of both, we determined the percentage of cell viability (Table 5) and
observed that exposure to both ABT-737 and S63A45 resulted in massive cell
death at concentrations 10-fold lower (1µM) than the individual exposures (10µM)
that produced minimal if any cell death (Figure 10, S6).
Table 5: Percentage of Cell Viability for Established GBM cell Lines
GBM Cell Line

10µM ABT-737

10µM S63845

1µM ABT-737 +
1µM S63845

H4

49.88 ± 5.25

53.08 ± 3.08

1.62 ± 0.72

SNB75

83.65 ± 1.20

71.17 ± 2.23

16.89 ± 0.82

A172

73.43 ± 9.49

93.05 ± 6.72

74.07 ± 21.32

SF268

80.70 ± 2.88

101.26 ± 4.31

44.38 ± 25.67

SF539

85.34 ± 5.62

84.08 ± 5.73

1.79 ± 0.41

SF295

82.63 ± 3.61

74.09 ± 2.25

3.02 ± 1.72

U87

69.67 ± 0.16

87.95 ± 3.25

22.96 ± 3.78

U251

85.21 ± 3.71

93.23 ± 4.22

63.80 ± 2.05

SNB19

87.06 ± 3.98

94.68 ± 3.65

64.75 ± 1.95

U118

48.97 ± 2.96

107.73 ± 6.54

73.29 ± 2.54

Percentage of cell viability for GBM cell lines was determined in a 96-well format
on 5x103 cells/well using cell-based fluorescence.
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Figure 10: Percentage of Cell Viability after treatment with Bcl-2 and Mcl-1 inhibitors in GBM Cell Lines.
(A) GBM cell lines were incubated for 72 hours in the presence of 0-10µM of ABT-737, 0-10µM S63845, or both. The
cells were then fixed and stained with CellTag 700 stain to determine the number of cells. Displayed in this figure are
the TMZ-sensitive lines (H4, SNB75) and the TMZ-resistant line (U251, SNB19). (B) The fluorescence for each TMZ
dose was plotted and comparisons between treatments was performed using ANOVA followed by Tukey’s honest test.
***p<0.001, ****p<0.0001
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4. Discussion
BH3-only profiling has been proposed as measure to predict the chemosensitivity
of solid tumors and certain types of leukemia; however, previous studies in GBM
showed that the individual expression levels of different members of the Bcl-2
protein superfamily did not correlate with patient overall survival (Potter and Letai,
2016) (Cartron et al., 2012). Our current study determined that while individual
expression of Bcl-2 family proteins is not sufficient to predict prognosis, a collective
assessment of anti-apoptotic and pro-apoptotic Bcl-2 proteins may be useful to
discern the personalized vulnerability of tumors. In fact, we demonstrate that the
ratio between the relative abundance of anti-apoptotic Bcl-2 proteins (Bcl-2, BclxL,

and

Mcl-1)

and

the

BH3-only

protein

Bim

levels

correlate

with

chemoresponsiveness to TMZ in established GBM cell lines. This was also the
case in patient-derived GSCs. Additionally, inducing chemoresistance in U87 cells
by hypoxic cycling decreases the anti-apoptotic Bcl-2/Bim ratio. The collective
contribution of anti-apoptotic Bcl-2 proteins to cell survival and chemoresistance
was verified using a Bim mimetic, ABT-737 (a Bcl-2 and Bcl-xL inhibitor), and a
Mcl-1 inhibitor, S63A45 to induce cell death and enhance TMZ potency in
established GBM cell lines and GSCs. Based on these findings, we propose that
an assessment of apoptotic capacity in GBM cells may be useful to determining
personalized treatment options.
Prognostic approaches for GBM currently entail sequencing of commonly mutated
genes and histological analysis of tumors, with the problematic hypermethylation
of the MGMT promoter losing its previously presumed clinical relevance. The
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genomic analyses include genes that are involved in growth and metabolism, and
only p53 has any relevance to apoptosis. The histological classification of the
tumor is based on the presence of specific cellular markers related to proliferation,
and none are reflective of cell death capacity. This is problematic, in our opinion,
when assigning therapies because one cannot be certain if a chemotherapy or
radiotherapy approach will be effective without insight into the relative potential for
GBM tumor cells to undergo apoptosis. Our suggested approach of histological or
biochemical assessment of anti-apoptotic Bcl-2 proteins and Bim in GBM
specimens would provide an index for the relative chemoresistance based on the
collective abundance of Bcl-2, Bcl-xL, and Mcl-1, and give insight into the apoptotic
induction threshold by assaying the relative concentrations of Bim. Of course,
further studies in healthy patients and GBM patients will be needed to assess what
concentrations will correlate to clinical outcomes. This will be a topic of research
between the lab and Baptist Health South Florida as part of a collaborative project
to improve GBM prognosis and treatment selection.
In our study, we found that only one BH3-only protein concentration, Bim, reflected
cell death capacity in GBM cell lines and GSCs. Bim is able to promote apoptosis
by either direct activation through Bak and Bax, or by sequestering Bcl-2 antiapoptotic proteins (Chipuk and Green, 2008). The relative abundance of Bim on
mitochondria is controlled in part by increased gene expression and by posttranslational modification by stress-induced kinases. In fact, the c-Jun N-terminal
kinase (JNK) can phosphorylate Bim in response to chemo- and radiotherapy. JNK
phosphorylation of Bim induces mitochondrial translocation where it can impair
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anti-apoptotic Bcl-2 proteins and trigger mitochondrial outer membrane
permeabilization (MOMP) leading to apoptosis (Lei and Davis, 2003). Based on
Bim’s actions, we assert that Bim levels are a critical marker for a cell’s ability to
readily induce apoptosis under basal conditions. In fact, Bim mimetics, such as
ABT-737, and related compounds are being explored as chemo-sensitizing agents
because of their ability to increase apoptotic thresholds. However, based on the
results of our current study, we propose that Bim concentrations should be
examined with respect to the abundance of Bim targets such as the anti-apoptotic
Bcl-2 proteins. We find that the ratio between anti-apoptotic Bcl-2 proteins and Bim
is a more accurate predictor of chemoresponse and could be used to stratify
patients (Figure 3) because the ratio reflects the relative capacity of Bim to inhibit
anti-apoptotic proteins. For example, in a Bcl-2/Bim ratio greater than 1 in a tumor
sample, one may need to employ a sensitizing agent before a treatment approach
to lower the apoptotic threshold; where, a ratio below 1 may indicate that a tumor
may require less aggressive treatment approaches because of a lower cell death
threshold. Additionally, changes in the Bcl-2/Bim ratio can be monitored as
mechanism to track acquired resistance in GBM patient samples (Figure 9). It
should be noted that the inclusion of Mcl-1 could affect the accuracy of the ratio
because Mcl-1 translocation to mitochondria and sequestration to cytosol is related
in part to the scaffold 14-3-3 and the actions of another BH3-only protein, Noxa, in
other solid tumors (Nakajima et al., 2014). Therefore, the Bcl-2/Bim ratio may need
to be supplemented with pharmacological profiling with ABT-737 and S63845 to
determine the relative survival capacity of GBM tumor cells.
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Our current study as indicated above suggests that chemoresponsiveness and cell
survival is influenced by the concerted activities of anti-apoptotic proteins Bcl-2,
Bcl-xL, and Mcl-1 on the mitochondrial surface. This was somewhat expected
given the common functions of these three proteins. The fact that the
concentrations of these proteins alone can be used in conjunction with Bim levels
is indeed surprising because of the levels of control in place to coordinate the
activities of Bcl-2 proteins to sustain cell viability or to induce apoptosis. For
example, the presence of Bcl-2 alone does not always dictate functions.
Phosphorylation of Bcl-2 has been shown to affect the balance between survival
and cell death. Phosphorylation of residues threonine 56 (Thr56) and serine 87
(Ser87) are necessary for the anti-apoptotic functions of Bcl-2, as mutation of these
residues (Thr56Ala and Ser87Ala) failed to prevent glucocorticoid-induced cell
death in T-cells (Huang and Cidlowski, 2002). Alternatively, JNK-mediated
phosphorylation of Bcl-2 has been shown to induce Bcl-2 migration from the outer
mitochondrial membrane and prevent its anti-apoptotic actions. Similar phosphoregulatory mechanisms have been proposed to influence the activities of Bcl-xL,
Mcl-1, and BH3-only proteins, such as Bim. Accordingly, if the concentrations of
anti-apoptotic Bcl-2 proteins and Bim lose correlation power in patient samples, it
may be prudent to consider the phosphorylation state of the proteins when
assessing apoptotic capacity and predicting potential therapeutic outcomes.
Finally, treatment of GBM cell lines and GSCs with the BH3 mimetic ABT-737 or
the Mcl-1 inhibitor S63845 only modestly affected cell viability. However, exposure
to both ABT-737 and S63845 resulted in massive cell death at concentrations 10-
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fold lower (1µM) than the individual exposures (10µM) that produced minimal if
any cell death. This observation emphasizes the importance of all three antiapoptotic Bcl-2 proteins to the establishment of the apoptosis threshold. The data
also demonstrate the importance of Mcl-1 levels to the anti-apoptotic capacity
because ABT-737 has binding affinity for Bcl-2, Bcl-xL and Bcl-w and not Mcl-1
(Oltersdorf et al., 2005). The synergism between ABT-737 and S63845 was
apparent when these compounds increased the efficacy of TMZ in the nanomolar
range. This benefits patients as the use of ABT-737 and S63845 could lower the
dose of the highly toxic TMZ and reduce the risk of potentially debilitating off-target
effects in the brain. Unfortunately, Bcl-2 proteins are ubiquitously expressed in the
brain, and toxicity studies would need to be performed to assure that the doses
used would not adversely affect non-tumor cells in the brain. Without selective
targeting to tumor cells, we could render neurons and glial cells vulnerable to the
treatments that follow ABT-737 and S63845 by increasing the apoptotic potential
in these cells, which may result in permanent neurological damage. Fortunately,
similar compounds are in clinical trials or in use and few side effects have been
reported. Suggesting that low dose chemosensitization with BH3-mimetics may be
a useful approach to improve GBM outcomes.
In our current study, we explore mitochondrial factors that contribute to
chemotherapeutic resistance in GBM cell lines and GSCs. We found that the
relative abundance of anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) and the
BH3-only protein Bim could be used to predict chemotherapeutic outcomes;
furthermore, inhibition of anti-apoptotic Bcl-2 proteins was found to increase
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chemotherapeutic efficacy. Moreover, the inhibition of Bcl-2, Bcl-xL, and Mcl-1
synergistically enhanced the potency of TMZ. Based on our results, we contend
that rigorous assessment of Bcl-2 proteins may be a useful approach to determine
if specific treatments will be effective in GBM patients. Future studies will focus on
determining the relevant concentrations required to predict outcomes in patient
tumors and previously-acquired histological samples.
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CHAPTER IV
A novel splice variant of Sab alters mitochondrial physiology

108

1. Introduction
The Bcl-2 superfamily of proteins are critical modulators of cell death responses in
human cells, and dysregulation of Bcl-2 proteins can result in human disease.
Specifically, the accumulation of anti-apoptotic Bcl-2 proteins, such as Bcl-2, BclxL, and Mcl-1, may enhance the survival of cancer cells by increasing the cells’
tolerance to toxic challenges (Brunelle and Letai, 2009). Alternatively, an
overabundance of pro-apoptotic Bcl-2 proteins (BH3-only proteins) may lower the
apoptotic threshold of cells by inhibiting the actions of anti-apoptotic proteins and
promoting mitochondrial outer membrane permeabilization (MOMP) by facilitating
the oligomerization of Bax and Bak (Chipuk et al., 2008). Proteins in the Bcl-2
superfamily are tightly regulated by gene expression and by post-translational
modification. Phosphorylation of Bcl-2 proteins can differentially influence the antiand pro-apoptotic functions of these proteins. This phospho-regulation connects
apoptotic machinery to cellular growth and stress response pathways.
One of the most prominent stress-responsive regulators of Bcl-2 function is the cJun N-terminal kinase (JNK), a serine/threonine protein kinase, that can influence
activities

of

both

anti-apoptotic

and

pro-apoptotic

Bcl-2

proteins

by

phosphorylation. JNK can affect the anti-apoptotic functions of Bcl-2 differently
depending on the phosphorylation site. For example, JNK phosphorylation on
threonine-56 (Thr56) and serine-87 (Ser87) are required for the anti-apoptotic
functions of Bcl-2, and mutation of Thr56 and Ser87 prevents the survival functions
of Bcl-2 (Huang and Cidlowski, 2002). Alternatively, JNK phosphorylation of Bcl-2
on Ser70 leads to emigration of Bcl-2 from the outer mitochondrial membrane
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(OMM) and promotes apoptosis (Yamamoto et al., 1999). JNK also alters the
functions of Bcl-xL and Mcl-1 by phosphorylation. With respect to Bcl-xL, JNK
phosphorylation on residues Thr47 and Thr115 prevents apoptosis, while JNK
phosphorylation of residue Ser62 on Bcl-xL promotes chemotherapy-induced cell
death (Kharbanda et al., 2000). Similarly, JNK phospho-regulation of Mcl-1
influences cell death responses; whereby, JNK phosphorylation of Mcl-1 on
Thr163 results in the proteosomal degradation of Mcl-1 in a glycogen synthase
kinase-3

(GSK3)-dependent

manner

(Morel

et

al.,

2009).

Also,

JNK

phosphorylation of Mcl-1 on Ser121 and Thr163 have been linked to a decrease
in the pro-apoptotic and anti-apoptotic capacities, respectively (Thomas et al.,
2010). Depending on the kinase isoform, stimuli, and cellular context JNK signaling
can impact anti-apoptotic Bcl-2 proteins differently and influence cell fate.
However, JNK signaling seems to be more straightforward when it comes to the
regulation of pro-apoptotic BH3-only proteins. JNK primarily activates and
enhances the apoptotic activities of BH3-only proteins by phosphorylation. JNK
phosphorylation of Bim species are perhaps the most well characterized of the
JNK-Bcl-2 phospho-regulations. JNK phosphorylation on Ser44, Thr56, and Ser58
are all linked to enhanced apoptotic activities, including Bax-Bak oligomerization,
of Bim (Lei and Davis, 2003). Inhibition of JNK in many cell lines has been shown
not only to reduce Bim activity, but also resulted in decreased Bim levels. Bad is
also another BH3-only protein that can be induced by JNK phosphorylation as well.
JNK modification of Bad on Ser128 causes its release from the inhibitory scaffold
14-3-3; meanwhile, JNK phosphorylation on Thr201 of Bad enhances the
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interaction of Bad with Bcl-xL, which effectively sequesters and inhibits the antiapoptotic activities of Bcl-xL. JNK can also promote the gene expression of BH3only proteins (Wang et al., 2007; Yu et al., 2004). One example is JNK
phosphorylation of c-Jun (a component of the transcription factor activator protein1 (AP-1)) leads to the transcription of death protein-5/harakari (DP5/Hrk) (Ma et
al., 2007). Collectively, these results strongly support JNK’s role in apoptosis.
Stress-induced activation of JNK causes the translocation of the kinase to the
OMM, an event that culminates in mitochondrial dysfunction and apoptosis (J. W.
Chambers et al., 2011). The localization of JNK to the OMM places it close to not
only the bioenergetic machinery, but also Bcl-2 proteins. At mitochondria, JNK
interacts with the OMM scaffold protein Sab through a kinase interaction motif
(KIM) located in the C-terminus of Sab (Wiltshire et al., 2004; 2002; Win et al.,
2011). Mitochondrial JNK signaling promotes mitochondrial dysfunction by
amplifying reactive oxygen species (ROS) production, impairing bioenergetics,
and altering mitochondrial membrane potential (J. W. Chambers and LoGrasso,
2011; Hanawa et al., 2008). In addition, mitochondrial JNK signaling also plays a
role in cell death as mentioned above (J. W. Chambers et al., 2011; Schroeter et
al., 2003). Consequently, inhibition of the JNK-Sab interaction prevents oxidative
stress, mitochondrial dysfunction and cell death. Furthermore amplification of
JNK/Sab-mediated signaling has been shown to sensitize cancer cells and
improve chemotherapeutic efficacy (J. W. Chambers et al., 2011; 2013a; 2013b;
T. P. Chambers et al., 2015; Wiltshire et al., 2004). In fact, our recent studies in
gynecological cancers, reveal that Sab levels correlated with chemosensitivity;
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wherein, low Sab levels are indicative of chemo-resistant cells. Artificial elevation
of Sab was shown to increase the levels of BH3-only proteins on mitochondria,
while anti-apoptotic Bcl-2 protein concentrations were reduced in cells with
elevated Sab levels. However, toxin-induced increases in Sab also sensitized
normal cells to apoptosis. Cardiomyocytes exposed to prolonged low doses of
imatinib had increased Sab levels and were vulnerable to chemotherapeutic
agents and mitochondrial stress. These data suggest that JNK signaling on Sab is
a critical event in cell death signaling.
Because of the relevance of JNK-Sab signaling to cell death and the correlation of
Sab levels to chemo-responsiveness in gynecological malignancies, we
hypothesized that Sab levels would reflect the chemo-vulnerability of GBM cells.
We found that the Sab levels did not correlate to the responsiveness of cells to
TMZ. Sab levels did not correspond to Bcl-2 or BH3-only profiles as well. However,
we observed that a truncated version of Sab was expressed in some of the GBM
cell lines. Sequence analysis of the Sab transcripts revealed that the smaller form
of Sab was isoform 2, which lacks the first 157 amino acids of the protein. Cellular
characterization of the Sab variant reveals that it is localized to mitochondria using
a cryptic mitochondrial localization signal. The presence of the truncated Sab does
not alter apoptotic signaling or sensitivity to chemotherapeutic challenge. The
presence of the Sab variant does enhance glycolysis by way of impaired
respiration. Cells with the splice variant have diminished basal respiration and
spare respiratory capacity that can be attributed to diminished complex I activity.
These data suggest that Sab-mediated signaling may also be important to the
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regulation of bioenergetics in brain malignancies with minimal contributions to
apoptotic capacity.
2. Materials and Methods
Materials: GBM cell lines, A-172 (CRL-1620), H4 (HTB-148), U-87 MG (HTB-14),
and U-118 MG (HTB-15), were purchased from American Type Culture Collection
(Manassas, VA). The remaining GBM cell lines were obtained through the National
Institutes of Cancer (NCI) from the NCI-60 cell panel. Cell culture media was
purchased from Invitrogen (Grand Island, NY), and serum was purchased from
Denville Scientific (South Plainfield, NJ). General chemicals were purchased from
Fisher Scientific (Pittsburgh, PA) and Sigma Aldrich (St. Louis, MO) as indicated
below. Unless indicated below, antibodies were purchased from Cell Signaling
Technology (Danvers, MA).
Cell Culture: GBM cell lines were grown under normal cell culture conditions (37oC
and 5% CO2 with humidity). A-172, H4, U-87 MG, U-118 MG cells and the cells
from the NCI-60 panel (SF-268, SF-295, SF-539, SNB-19, SNB-75 and U-251)
were grown in Dulbecco’s Modified Essential Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1,000 U/mL penicillin, 100µg/mL streptomycin, and
5µg/mL plasmocin.
SF268 clonal selection: To isolate cells with specific Sab expression patterns, full
length versus splice variant, SF268 cells were plated as single cells in a 96-well
plate and expanded to obtain a clonal population of cells.
Cell Lysis and Western Blot Analysis: To isolate proteins from cells for analysis,
cells were plated at 2.5x105 cells/well in a six well plate unless otherwise indicated.
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Following treatment, cells were lysed, and proteins were harvested as previously
described. Briefly, cells were washed twice in phosphate buffered saline (PBS;
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4) and lysed in
radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH 8.0, 150mM
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 1mM
phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase
Inhibitor Cocktails (Thermo Scientific). Cells were incubated while gently rocking
at 4°C for five minutes, and then transferred to a sterile micro-centrifuge tube. After
two minutes on ice, cell disruption was completed using sonication. The lysate was
cleared by centrifugation at 15,000 × g for 15 minutes. Protein concentrations of
the supernatant were measured using the Pierce BCA Assay kit according to
manufacturer’s directions. Proteins were then resolved by SDS-PAGE and
transferred onto low fluorescence PVDF membranes. Membranes were placed in
blocking buffer comprised of TBS supplemented with 5% bovine serum albumin
(BSA) and incubated for at least one hour at room temperature (RT) or overnight
at 4°C. The membranes were incubated in TBS containing 0.1% Tween 20 (TBSt)
and 5% BSA in the presence of primary antibodies for at least 2.5 hours (RT) or
overnight (4oC) while gently rocking. Primary antibodies specific for Sab (Novus,
H00009467-M01), Calnexin (CST, 2679), CoxIV (CST, 4850) Actin (CST, 4970),
and α-tubulin (CST, 2144) were used at dilutions of 1:1000 for these studies.
Membranes were washed three times for five minutes in TBSt. Membranes were
incubated with secondary antibodies in the appropriate blocking buffer at a ratio of
1:20,000 for one hour at RT gently rocking. The following secondary antibodies
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were used in the experiments below: IRDye 680RD Goat anti-Rabbit (926-32211)
and IRDye 800CW Goat anti-Mouse (926-68070) (Licor Biosciences). Membranes
were again washed three times for five minutes in TBST. Membranes were
analyzed using fluorescence detection using the Odyssey CLx near infrared
scanner (Licor Biosciences). The corresponding bands on the western blots were
quantified and normalized using the Image Studio 2.0 software (Licor Biosciences).
The fluorescence of specific bands of interest were divided by the fluorescence of
the loading control band to equilibrate signal strength and loading. The resulting
signal was then normalized by dividing the signals from treated samples by
respective untreated or normal tissue control signals for each experiment.
Defining the cellular distribution of the Sab splice variant using confocal
microscopy: GBM cell lines, SF268 and SF268 clone #6 were plated in 12-well
plates containing 18mm glass coverslips in each well bottom at a density of 7x104
cells per well. The cells were incubated with 50nM Mitotracker Deep Red FM
(M22426) (ThermoFisher Scientific) for 15 minutes at 37 oC protected from light,
and

then

fixed

by

incubation

with

4%

paraformaldehyde/PBS.

Immunofluorescence was performed to detect Sab (as described in (J. W.
Chambers et al., 2013b). Briefly, cells were placed in permeabilization/blocking
buffer comprised of PBS with 5%BSA, 0.2% tween and 0.1% triton X-100 for 30
minutes at RT. The coverslips were incubated with PBS containing 0.1% Tween
20 (PBSt) and 5% BSA in the presence of primary antibodies against Sab
(H00009467-M01) (Novus Biologicals) overnight at 4oC. Cells were washed three
times for five minutes in PBSt. Coverslips were incubated with secondary antibody
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AlexaFluor-488 anti-Mouse (CST-4408) in the appropriate blocking buffer at a ratio
of 1:250 for one hour at RT gently rocking. Coverslips were again washed three
times for five minutes in PBSt. Coverslips were mounted on microscopy slides
using DAPI Fluoromount-G (0100-20) (SouthernBiotech). Cells were imaged using
a confocal microscope Fluoview FV1000 (Olympus).
Mitochondrial Isolation: A modified protocol as described in (Magalhães et al.,
1998; Yang et al., 1997) was used to obtain mitochondria as described in our
previous studies (J. W. Chambers et al., 2013b; 2013a; 2011). Mitochondrial
samples with greater than 80% purity were used for experiments.
Metabolic Analysis: Cellular metabolism was assessed by measuring the
extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) of
the GBM cell line SF268 and SF268 Clone #6 using the Seahorse Biosciences XF96 extracellular flux analyzer (Wu et al., 2007). Cells were assayed (1.0x104
cells/well) using the glycolytic and mitochondrial stress kits. For our studies, 3.0µM
oligomycin, 1µM FCCP, 3µM rotenone and 3µM antimycin were used. From these
measurements, we derived glycolytic and respiratory parameters, including spare
respiratory capacity as previously described (Wu et al., 2007). Data were
normalized to cell number.
Cell proliferation by BrDU incorporation: We measured cellular abundance by
incorporation of 5-bromo-2'-deoxyuridine (BrdU) cell proliferation assay. We used
the BrdU Cell Proliferation assay kit (Cat# 11669915001) (Roche). GBM cells
SF268 and SF268 clone #6 were plated at a density of 0.5 x104 cells per well and
grown overnight. The cells were then serum starved for 24 hours. After serum
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starvation, cells were treated with increasing concentrations of FBS for 24 hours
and then monitored BrdU incorporation using the manufacturer’s protocol for 24
hours. Light emission was measure using the Synergy H1 Hybrid Reader (BioTek).
Determining Cell-based IC50s for Irinotecan and Rotenone: To determine the
relative chemo-sensitivity of the GBM cell line SF268 and SF268 Clone #6, cells
were treated with increasing concentrations of either Irinotecan (0-15µM) or
Rotenone (0-10µM). Briefly, GBM cells were plated at 5x103 cells per well in blackwalled, clear bottom plates (Perkin Elmer) and grown overnight. The cells were
then treated with chemotherapeutic agents for 72 hours. The cells were washed
three times in PBS and fixed in 4% paraformaldehyde/PBS. The cells were then
stained with 0.2µM CellTag 700 Stain (926-41090) (Licor Biosciences) for 1 hour
at RT. The cells were then washed three times in Hank’s Buffered Saline Solution
(HBSS). The plate was imaged using the Odyssey CLx scanner (Licor
Biosciences) and analyzed using the Image Studio 2.0 software (Licor
Biosciences). The IC50 for each cell line was calculated using the GraphPad
Prism7© software.
Caspase Activity: To assess caspase 3/7 activity in SF268 and SF268 clone #6
cell lines after treatment with either irinotecan or rotenone, cells were grown on 6well plates. After treatment, cells were lysed with 100µL of PBS supplemented with
1% TritonX-100, for 5 minutes on ice. Cell disruption was completed by sonication,
and samples were centrifuged at 15,000 x g for 10 minutes at 4oC. Then, 25µL of
the lysate was transferred to a black 96-well plate and incubated with 200µL of the

117

substrate solution comprised of PBS, with or without 25µg/ml of caspase substrate
Ac-DEVD-AMC (37µM) in PBS supplemented with 5mM DTT. The assay
incubated at 37oC for 30 minutes, and fluorescence was measured (excitation:
380nm; emission: 440nm).
Biological Replicates and Statistics: A minimum of four biological replicates were
used for cell-based studies, with a minimum of six experimental replicates. To
evaluate differences between sample groups, the Mann-Whitney test was used.
Experiments with more than three comparison groups were subjected analysis of
variance (ANOVA) followed by the Tukey Honest Difference test to compare
means. An asterisk in figures indicated p value is less than 0.05. Data are
displayed as means with error bars representing plus and minus one standard
deviation of the mean.
3. Results
3.1 Sab protein levels are distinct among GBM cell lines. Sab levels have been
shown to correlate to chemo-responsiveness in gynecological cancers, we
examined if Sab levels would reflect the chemo-responsiveness of GBM cells. We
observed no discernable pattern between Sab expression levels and chemoresponsiveness, Sab levels were comparable in the sensitive line H4 and the
resistant line U118 (Figure 11). Intriguingly, we observed a second molecular
weight species of Sab, suggesting the presence of a novel Sab splice variant in
certain GBM cell lines. The transcript for a splice variant of Sab has been identified
(Ota et al., 2004), it has a shorter N-terminus (Figure 12), and its predicted
molecular weight corresponds to the species observed in SF268 cells.
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Figure 11. Expression of Sab in different GBM cell lines.
GBM cell lines were grown to 85% confluency and lysed. Proteins (25µg) were
quantified and resolved by SDS-PAGE. (A) Western blot analysis was used to
detect Sab levels. Tubulin was used as loading control. (B) Quantification of
expression levels.

Figure 12. Schematic representation of Sab splice variants.
(A) Sab full-length. (B) Sab splice variant. This representation of the Sab splice
variants shows the different regions of each splice variant. CC1: coiled-coiled motif
1, CC2: coiled-coiled motif 2, TM transmembrane domain, KIM1: kinase interaction
motif 1, KIM2: kinase interaction motif 2, S: phosphorylation sites.
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3.1 Expression of the Sab splice variant is heterogenous in a population of
cells. We selected SF268 cells to determine if the Sab variant is homogenously
expressed across an entire population of cells. We developed 11 different SF268
clones by expanding a population of cells that originated from a single cell. The
expression of the Sab splice variant was heterogenous among clones, showing
different levels of expression of the variant and/or ratios between Sab full-length
and Sab variant. From the 11 clones developed, SF286 clone #6 was the only
clone that didn’t express the variant and therefore was selected for our future
comparative studies (Figure 13).
3.2 Sab splice variant localizes to mitochondria. Because the mitochondrial
localization signal is located in the N-terminus of Sab, a shorter N-terminus for the
splice variant suggests that it lacks the canonical mitochondrial localization signal
and the Sab variant will have a distinct cellular localization. To determine the
cellular localization of the Sab splice variant we performed co-localization studies
between immunofluorescence against Sab and the mitochondrial specific dye
Mitotracker Deep Red FM. We did not observe any differences in Sab distribution
between SF268 cells that express both Sab full-length and the variant (Figure
14A), and SF268 clone #6 that only expresses Sab full-length (Figure 14B). Our
immunofluorescence

localization

findings

were

validated

by

subcellular

fractionation and mitochondrial isolation that showed the Sab splice variant only in
the mitochondrial fraction and not in the cytosolic fraction (Figure 15).
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Figure 13. Sab variant expression among a population of SF268 clones.
(A) SF268 clones were grown to 85% confluency and lysed. Proteins (25µg) were
quantified and resolved by SDS-PAGE. Western blot analysis was used to detect
Sab levels. Actin was used as loading control. Sab expression levels were
measured using an antibody against the C-terminus (B) and quantified (C)

121

Figure 14. Cellular distribution of Sab in SF268 cells.
Confocal microscopy images were obtain using the GBM cell line SF268 (A) and
SF268 clone #6 (B), cells were stained with DAPI (nucleus), Mitrotacker Deep Red
FM (mitochondria) and Sab.
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Figure 15. Cellular fractionation and Sab distribution.
Subcellular fractionation was performed from SF268 and H4 cells and analyzed
for the presence of Sab. Proteins (25µg) were quantified and resolved by SDSPAGE. Western blot analysis was used to detect Sab levels. Mitochondrial
enrichment was determined by the relative abundance of COX-IV, contamination
by other subcellular compartments was determined: cytosol (Actin), ER (Calnexin).
3.4 Sab variant expression reduces oxidative metabolism. To determine if the
expression of the Sab variant has an effect on mitochondrial physiology, we
measured mitochondrial respiration and glycolysis. We observed a 35% decrease
in basal respiration in SF268 cells (Figure 16A), which express the Sab variant,
while SF268 clone #6 have 60% more spare respiratory capacity (Figure15B),
reduced basal glycolysis (Figure 16C, and increased capacity for pyruvate
oxidation (Figure 16E, F). Together these observations suggest that expression of
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Figure 16. Sab variant expression reduces oxidative metabolism.
The respiratory profile of cells with and without the Sab splice variant was measured using the Seahorse XF-96
extracellular flux analyzer. (A) Basal respiration (B) spare capacity (C) basal glycolysis, (D) OCR/ECAR ratio, (E)
Pyruvate oxidation and (F) pyruvate oxidation capacity. Comparisons between groups was performed using the MannWhitney test.
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the Sab variant affects mitochondrial oxidative metabolism by reducing the cell’s
respiratory capacity.
3.5 Sab splice variant expression increases cell proliferation. To determine if
expression of the Sab splice variant had an effect on cellular physiology, we
compared cellular proliferation and viability between cells with and without Sab
variant expression. SF268 and SF268 clone # 6 cells were treated with increasing
concentrations of FBS (0-10%) for 48 hours. We observed that SF268 cells that
expressed the Sab variant had increased cell viability in comparison to SF268
clone #6 cells in a dose dependent manner when treated with increasing
concentrations of FBS (Figure 17A). SF268 cells also had increased cellular
proliferation, specially at lower serum concentrations, in comparison to SF268
clone #6. At higher serum concentrations there was no significant difference in
proliferation rates (Figure 17B).
3.6 Sab variant expression increases chemosensitivity. To determine if Sab
variant expression also has an effect on chemoresponse, we measured cell
viability in SF268 and SF268 clone #6 cells after treatment with increasing
concentrations with either irinotecan or rotenone. We observed a more
pronounced decrease in cell viability in SF268 cells (Figure 18), suggesting that
the Sab splice variant expression improves chemosensitivity. To determine if
decreased viability was due to an increase in apoptosis we measured caspase
activity in SF268 and SF268 clone #6 cells treated with either irinotecan (3.5µM)
or rotenone (1µM) for 24, 36 and 48 hours, staurosporine (1µM) was used as a
positive control. We did not observed differences in response between SF268
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cells and SF268 clone #6, irinotecan induced a more robust caspase activation
than rotenone and the positive control staurosporine in both cell lines (Figure 18C
&17F). These results suggest that changes in drug response and cell viability
elicited by the Sab variant are independent of caspase activation.

Figure 17. Sab splice variant increases cell viability and proliferation.
SF268 and SF268 clone #6 cell lines were incubated for 48 hours with increasing
concentrations of FBS (0-10%). (A) The cells were then fixed and stained with
CellTag 700 Stain to determine cell viability (B) Fluorescence quantification for
each FBS dose. (C) Cell proliferation was measured by BrdU incorporation.
Comparisons between groups was performed using the Mann-Whitney test.
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Figure 18. Determining IC50 values for Irinotecan and Rotenone in SF268 Cell Lines.
(SF268 and SF268 clone #6 cell lines were incubated for 72 hours in the presence of 0-15µM Irinotecan (A) or 0.00510µM Rotenone (D). The cells were then fixed and stained with CellTag 700 stain to determine the number of cells. The
fluorescence for each of irinotecan (B) or rotenone (E)dose was plotted and the IC50 value was calculated using
GraphPad® Prism. Induction of apoptosis by 3.5µM Irinotecan (C) or 1µM rotenone (F) was measured by caspase
activation, STS was used as a positive control. Comparisons between groups was performed using the Mann-Whitney
test.
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4. Discussion
The scaffold protein Sab is involved in outer membrane mitochondrial signaling
and it plays a role in mitochondrial dysfunction and apoptosis (J. W. Chambers
and LoGrasso, 2011; T. P. Chambers et al., 2015). Our current study focused on
characterizing a novel Sab splice variant that we recently discover in GBM cell
lines. We found that expression of the Sab variant only occurs in some GBM cell
lines. In particular, SF268 cells had the highest variant expression levels; however,
within a population of these cells expression is heterogenous with some cells
expressing both the full-length and the truncated variant, while others only express
only full-length Sab. No cells were found to express only the variant. This was an
interesting observation that suggests isoform 1 of Sab (full-length) is necessary for
cellular function. This is also reflected by our unpublished attempts to make global
Sab knockout mice. Mice that are homozygous for the Sab knockout cassette die
before day 7 of embryogenesis. These data highlight a yet to be described
essential activity for Sab-mediated signaling beyond the induction of apoptosis.
Despite our initial hypothesis that the truncated form may be in the cytosol acting
as a JNK inhibitor, we found that the Sab splice variant localizes to mitochondria
according to immunolocalization and subcellular fractionation. A closer analysis of
the protein sequence reveals that there is a polycationic stretch of lysines and
arginines near the N-terminus of the polypeptide that resemble cryptic
mitochondrial localization sequences. Consequently, this means that both sab
isoforms would have cytosolic KIM2 motifs for JNK (or other MAPK interactions).
The transmembrane motif is intact meaning that the KIM1 motif is likely obscured
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by the OMM. This means that the variant (isoform 2) still has a functional SH3motif within the coil-coiled 2 (CC2) domain. However, the CC1 domain is gone.
This means that Sab isoform 2 has lost a protein-protein interaction site. With the
CC2 motif looking extremely familiar to a dimerization domain (and our preliminary
data support that Sab is a dimer) it is probable that CC1 interacts with proteins in
the intermembrane space. Perhaps, the protein interacting with CC1 in full-length
Sab is an inhibitor of complex I; thus, in Sab isoform 2, the inhibitor is released and
would explain the diminished respiration in cells possessing the variant. Previous
studies, have shown that stress-induced mitochondrial JNK signaling leads to Sabmediated inhibition of respiratory complexes, specifically complex I (J. W.
Chambers and LoGrasso, 2011). Unlike Sab full length, the truncated N-terminus
of the Sab splice variant is missing the first coiled coil motif, as a scaffolding protein
Sab interacts with other proteins acting as a signaling hub while providing stability
to protein complexes and losing a site for protein-protein interaction likely has
profound downstream effects (Strauss and Keller, 2008). Additionally, Win and
colleagues showed that when active JNK binds Sab on the outer mitochondrial
membrane a conformational change releases the protein phosphatase SHP1 in
the inner mitochondrial space, leading to intramitochondrial Src inactivation and
electron transport inhibition (Win et al., 2016). We predict this missing coiled coil
motif is required for proper regulation of Sab-mediated inner mitochondrial
signaling, either because of its interacting partners or due to required
conformational changes in Sab structure for proper signal transduction.
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The metabolic shift observed in cells expressing the Sab splice variant may confer
an advantage that allows cells to show increased proliferation (Figure16).
Utilization of glucose for aerobic glycolysis produces a series of precursors for
macromolecule synthesis, such as fatty acids, nonessential amino acids and
nucleotides (Vander Heiden et al., 2009).
Surprisingly, we also observed that cells expressing the Sab variant are not more
susceptible to both genotoxic and mitochondrial stress (Figure 18). Enhanced Sabmediated signaling has been linked to chemosensitization (T. P. Chambers et al.,
2015) However, the lack of difference in caspase activation and the failure to
display changes in Bcl-2 proteins may suggest that the OM scaffolding properties
of Sab remain intact and mitochondrial JNK signaling on the OMM proceeds as
normal.
In summary, we propose that the splice variant of Sab reduces oxidative
metabolism by inhibiting complex I activity, promoting a metabolic shift that
contributes to increased proliferation.
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CHAPTER V
Sab-Mediated Signaling Influences Metabolism and Chemosusceptibility in
Human Neuroblastoma Cells.
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1. Introduction
Neuroblastoma is a prevalent pediatric cancer accounting for approximately 15%
of cancer-related deaths in children (Maris, 2010). Late stage neuroblastomas are
resistant to conventional treatments, including chemotherapy (Matthay et al., 2009;
Porro et al., 2010; Teitz et al., 2000). New therapeutic options targeting the unique
aspects of neuroblastomas are needed to treat late-stage malignancies and
improve patient survival.
Neuroblastoma cells undergo specific changes in metabolism to support growth
and develop resistance to apoptosis during oncogenesis. Metabolically, cells shift
their bioenergetic and biosynthetic processes to sustain proliferation and survival
(Vander Heiden et al., 2009). While cancer cells increase glucose utilization for
biosynthesis and ATP generation, tumor cells rely on mitochondrial reactions to
replenish the tricarboxylic acid (TCA) cycle and maintain reducing equivalents
(DeBerardinis et al., 2007). Glutamine utilization can replenish TCA cycle
intermediates and maintain mitochondrial integrity, redox homeostasis, and
macromolecular biosynthesis (Qing et al., 2012). Consequently, the unique
metabolism of tumor cells can be a predictive index for chemosensitivity and the
proteins responsible for metabolic changes may be useful neuroblastoma drug
targets (Ren et al., 2015; Sandulache et al., 2011; L. Yang et al., 2014).
The attenuation of apoptosis is a hallmark of cancers, including neuroblastomas
(Hanahan and Weinberg, 2011). Circumventing the pathways for apoptosis
involves manipulation of Bcl-2 protein function. Apoptotic evasion is associated
with increasing pro-survival Bcl-2 proteins (Bcl-2, Mcl-1, and Bcl-xL), while
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abundant BH3-only proteins (Bim, Bid, Puma, Noxa, etc.) indicate pro-apoptotic
mitochondria susceptible to treatments (Brunelle and Letai, 2009; Certo et al.,
2006; Chonghaile et al., 2011; Letai et al., 2002). In neuroblastoma, BH3-only
protein levels can be used to predict chemotherapeutic responses and resistance
(Goldsmith et al., 2012; 2010). The levels of Bcl-2 proteins and chemoresponsiveness has been well evaluated recently; however, the molecular
mechanisms responsible for controlling Bcl-2 proteins abundance on mitochondria
in neuroblastoma has yet to be fully delineated.
The c-Jun N-terminal kinase (JNK) can induce apoptotic signaling. JNK signaling
has been linked to induction of apoptosis and chemosensitization in
neuroblastoma cells (Cheng et al., 2014; Fey et al., 2015; Filomeni et al., 2003;
Waetzig et al., 2009). Previous research has demonstrated that mitochondrial JNK
is required to induce cell death responses (J. W. Chambers et al., 2011a; 2013a;
J. W. Chambers and LoGrasso, 2011; J. W. Chambers et al., 2013b; Nijboer et al.,
2013; Win et al., 2014). Silencing Sab, an outer mitochondrial scaffold protein, or
selectively inhibiting the interaction between JNK and Sab prevents JNK
translocation to mitochondria and decreases mitochondrial dysfunction (J. W.
Chambers et al., 2011a). Furthermore, blocking mitochondrial JNK translocation
impairs Bcl-2 emigration from mitochondria preventing apoptosis (Matthay et al.,
2009). Preventing mitochondrial JNK signaling is a useful means to block induction
of apoptosis in neuroblastoma cells (J. W. Chambers et al., 2013a; 2011b;
Kristiansen et al., 2010; Nijboer et al., 2013; Zhou et al., 2008). These studies
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demonstrate the influence of mitochondrial JNK signaling on apoptosis in
neuroblastoma.
In this study, we examined the impact of Sab-mediated signaling on mitochondrial
function and apoptosis in human neuroblastoma cells. We found that Sab
expression was significantly diminished in neuroblastoma patients. Inhibiting Sabmediated signaling decreased proliferation, reduced glycolysis, and increased
oxidative metabolism; meanwhile, over-expression of Sab resulted in decreased
pyruvate dehydrogenase and complex I activities. Sab-inhibited neuroblastoma
cells had more Bcl-2 proteins and less BH3-only proteins. Cells treated with an
inhibitory Sab peptide were less sensitive to chemotherapy agents. Finally, Sab
levels correspond to metabolic phenotype and chemo-sensitivity in a small panel
of neuroblastoma cells. Thus, Sab levels may be a useful prognostic biomarker for
neuroblastoma.
2. Materials and Methods
Gene Expression: The expression of Sab (SH3-binding protein 5; SH3BP5) was
examined using the Oncomine database (http://www.oncomine.org) in October
2017 (Rhodes et al., 2007). By querying four neuroblastoma datasets that included
Sab as part of past studies (Albino et al., 2008; Asgharzadeh et al., 2006;
Janoueix-Lerosey et al., 2008; Wang et al., 2006), we compared experimental data
for normal tissue, ganglioneuromas, and neuroblastomas. The data were compiled
from a total of 8 normal tissue samples and 286 neuroblastoma samples (Table
6).

138

Table 6: Summary of Neuroblastoma Expression Studies and Observed Changes in Sab Expression.
*The mean fold changes were generated by averaging the fold changes from the studies.

STUDY

TOTAL
SAMPL
ES
19

CANCER
SAMPLE
S
15

NORMAL
SAMPLES

NORMAL
TISSUE

GENES
ANALYZED

4

Ganglioneu
roma

ASGHAR
ZADEH

117

117

0

JANOUE
IXLEROSE
Y
WANG

56

53

102

TOTALS/
MEANS

294

ALBINO

LOG2
FOLD
CHANGE
-0.804

AVG.
FOLD
CHANGE
-1.75

P

REFERE
NCE

12,624

HUMAN
GENOME
ARRAY(S)
U113A

0.002

Albino, D.
Cancer.
(2008)

None

12,624

U133A

N/A

N/A

N/A

3

Ganglioneu
roma

19,574

U133
2.0

-1.22

-1.815

2.59
E-5

101

1

Fetal Brain

8,603

U95A-Av2

-2.20

-2.437

0.001

Asgharza
deh, S.
J.
Natl.
Cancer
Inst.
(2006)
JanoueixLerosey I.
Nature.
(2008)
Wang, Q.
Cancer
Res.
(2006)

286

8

-1.408

-2.001
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Plus

Materials: CHP-212 (CRL-2273), IMR-32 (CCL-127), SK-N-SH (HTB-11), and SHSY5Y cells (CRL-2266) were purchased from American Type Culture Collection.
General reagents were purchased from Fisher Scientific and Sigma Aldrich.
Cell Culture and Treatment with Peptides: Human SH-SY5Y neuroblastoma cells
were cultured as described in previously (Biedler et al., 1978). CHP-212, IMR-32,
and SK-N-SH lines, cells were grown in DMEM with 10% FBS, 100U/mL penicillin,
100µg/mL streptomycin, and 5µg/mL plasmocin. To inhibit Sab-mediated
signaling, cells were treated with either the Tat-SabKIM1 peptide or the TatScrambled peptide as described below and in our prior studies (J. W. Chambers
et al., 2013b; 2013a; 2011a).
Cell Proliferation: We employed two assays to measure cellular abundance: 5bromo-2'-deoxyuridine

(BrdU)

and

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) cell proliferation assays. First, we used the
BrdU Cell Proliferation assay kit (Cell Signaling Technologies). Neuroblastoma
cells were plated at a density of 0.8 x104 cells per well and treated as indicated
below. Cell growth was monitored using the manufacturer’s protocol over the
course of five days. Absorbance was read at 450nm. Similarly, we employed the
MTT Proliferation Assay (Cayman Chemical). Neuroblastoma cells were plated as
described for the BrdU assay, and the cells were cultured for up to five days. The
assay was performed following the manufacturer’s instructions. The absorbance
was measured at 590nm. The number of cells was calculated based on a standard
curve of known cell numbers and averaged between the two assays.
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Caspase Activity: To assess caspase 3/7 activity in neuroblastoma cell lines, cells
were grown on clear 96-well plates. The plate was centrifuged (400xg) for five
minutes, and the supernatant was removed. The cells washed in 150µL of PBS
and centrifuged (400xg for 5 minutes). Next, 100µL of PBS supplemented with 1%
TritonX-100 was added to lyse the cells. Following a 30-minute incubation on a
room temperature orbital shaker, the plate was centrifuged at 800xg for 10
minutes, and 90µL of the lysate was transferred to a black 96-well plate. Then,
10µL of PBS or 10µL of a caspase inhibitor (Ac-DEVD-CHO; 10µM) was added to
the well, and 100µL of caspase substrate Ac-DEVD-AMC (100µM) in PBS
supplemented with 20mM DTT was added last. The assay incubated at 37oC for
30 minutes, and fluorescence was measured (excitation: 488nm; emission:
535nm).
Metabolic Analysis: Cellular metabolism was assessed by measuring the
extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) of
neuroblastoma cells using the Seahorse Biosciences XF-96 extracellular flux
analyzer (Wu et al., 2007). Cells were assayed (1.5x104 cells/well) using the
glycolytic and mitochondrial stress kits. For our studies, 1.0µM oligomycin, 100µM
2-DOG, 50µM 5-thioglucose (5-tGlc), and 1µM FCCP were used. From these
measurements, we derived glycolytic and respiratory parameters, including spare
respiratory capacity as previously described (Wu et al., 2007). Data were
normalized to cell number.
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Mitochondrial Isolation: A modified protocol as described in (Magalhães et al.,
1998; J. Yang et al., 1997) was used to obtain mitochondria as described in our
previous studies (J. W. Chambers et al., 2013b; 2013a; 2011a). Mitochondrial
samples with greater than 80% purity were used for experiments.
Lactate Measurements: Lactate concentrations were measured in cell culture
media using a Lactate Assay Kit (MAK064, Sigma-Aldrich). Samples (10µL) were
added to a black-walled clear-bottom 96-well plate and combined with reagents
according to manufacturer’s instructions. After a 30-minute incubation, the
fluorescence was measured (excitation: 535nm; emission: 585nm). Lactate
concentrations were determined using a standard curve.
Glucose Uptake: To monitor glucose uptake, we utilized the IRDye® 800CW 2deoxy-D-glucose (2-DOG) probe from Li-Cor Biosciences (926-08946). Cells were
plated in a black-walled, clear bottom 96-well plate. Next, the 800CW 2-DOG probe
was added to the culture media to a final concentration of 20µM. After two hours,
the media was removed, and the cells were placed in warm Hanks Buffered Saline
solution (HBSS). The plate was imaged on a Li-Cor Odyssey CLx Imager and data
were analyzed using the ImageStudio software package (Li-Cor).
Enzyme Assays: To verify the metabolic changes, biochemical assays were
employed to assess pyruvate dehydrogenase complex and respiratory chain
complexes. For pyruvate dehydrogenase (PDH) complex, the PDH activity assay
kit was purchased from Sigma-Aldrich and conducted following manufacturer’s
instructions. Mitochondria [50µg (protein)] were used. Absorbance was measured
at 450nm. Enzyme activity was quantified using a standard curve using
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recombinant, active PDH and normalized to protein levels. For respiratory chain
assays, we used colorimetric analyses for activity in 100µg of mitochondria isolates
and normalized the data to mitochondrial protein concentrations. Specifically,
Complex I (NADH dehydrogenase) activity was analyzed with the MitoToxTM
Complex I OXPHOS Activity Assay kit (Abcam) according to the vendor’s
instructions.
Cellular Lysis and Western Blot Analysis: Cell lysis and western blotting were
performed as previously described (J. W. Chambers et al., 2013a; 2011b). Primary
antibodies for our studies were Sab (Novus Biologicals, H00009467-M01), β-actin
(Cell Signaling Technology (CST), 4970), α-tubulin (CST 2144), hexokinase-1
(CST #2024), hexokinase-2 (CST #2867), lactate dehydrogenase (CST #3582),
pyruvate kinase (CST #3190), pyruvate kinase M2 (CST #4053), pyruvate
dehydrogenase (CST #3205), GLUT-1 (CST #12939), GLUT4 (CST #2213), Bcl-2
(CST #2870), Bcl-xL (CST #2764), Mcl-1 (CST #5453), Bim (CST #2933), Bid
(CST, #2002), PUMA (CST, #12450), COX-IV (CST, #4850), Pyruvate
dehydrogenase E1a-subunit (Abcam, ab110334), MCT-1 (Santa Cruz, sc50324),
and MCT-4 (Santa Cruz, sc50329) and secondary antibodies used were IRDye
680RD Goat anti-Rabbit (926-32211) and IRDye 800CW Goat anti-Mouse (92668070) from Li-Cor. Western blots were developed using the Odyssey CLx (Li-Cor)
and quantified using the Image Studio software (Li-Cor).
Chemosensitivity: The IC50s for carboplatin, cyclophosphamide, doxorubicin,
etoposide, and vincristine in neuroblastoma cells were determined using the TOPRO-3 near-infrared dye (Invitrogen) as described in our previous studies (T. P.
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Chambers et al., 2015). General cytotoxicity measurements were performed at 2x
the IC50s for SH-SY5Y cells for carboplatin and vincristine.
Overexpression of Sab: To increase Sab levels in neuroblastoma cells, we
transiently transfected SH-SY5Y with plasmids designed to express Sab
(pLOC:Sab) or red fluorescent protein (RFP; pLOC:RFP) (T. P. Chambers et al.,
2015; 2017). Plasmid DNA and FugeneHD (Promega) were combined in Optimem
(Invitrogen) at a ratio of 1:9 and incubated for 15 minutes at RT before addition to
culture. Eight hours after the addition of the transfection complex to media, the
media was exchanged. Protein levels were assessed by western blot analysis at
72 hours post-transfection, and only cells that demonstrated a greater than fourfold increase in Sab expression were used.
Mitochondrial ROS Production: To determine if ROS generation was increased in
mitochondria, we assessed ROS levels using MitoSOX Red (Invitrogen). We used
the approach described in our previous studies (J. W. Chambers et al., 2013a;
2011a; J. W. Chambers and LoGrasso, 2011).
Statistical Analysis and Replicates: Biochemical and other cellular measures were
done with a minimum of six experimental replicates. Mitochondrial and protein
analysis experiments were performed on a minimum of three biological replicates.
To determine statistical significance, Mann-Whitney analysis was employed for
significance between treatments. Statistical significance is indicated by an asterisk
in figures in which the p-value is less than 0.05. Data are displayed as means with
error bars representing plus and minus one standard deviation.
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3. Results
3.1 Sab expression is decreased in neuroblastoma tumors. We found four
neuroblastoma patient datasets in the Oncomine repository (Rhodes et al., 2007)
that evaluated Sab expression (summarized in Table 6). Across 286
neuroblastoma clinical samples, we found that Sab was decreased in all the
studies an average of 2-fold in neuroblastoma patients compared to normal tissue
and ganglioneuroma controls. However, other pro-apoptotic JNK signaling genes
were not altered consistently among the studies (data not shown). Further analysis
revealed that Sab expression was decreased in recurrent neuroblastoma (-1.33fold), increased in tumors with Schwann cell rich stromata (1.62-fold), and Sab
expression did not change between neuroblastoma stages. These observations
suggest that altered Sab expression may impact neuroblastoma physiology.
3.2 Inhibition of Sab-mediated signaling slows proliferation. JNK signaling on
Sab can be inhibited using a peptide (Tat-SabKIM1) in human SH-SY5Y
neuroblastoma cells (J. W. Chambers et al., 2013a). To discern if neuroblastoma
cells were affected by diminished Sab-mediated events, we measured cellular
proliferation in the presence and absence of the Tat-SabKIM1 inhibitor. SH-SY5Y
cells were treated with increasing concentrations of the Tat-SabKIM1 peptide (025µM) or scrambled control (Tat-Scramble) for five days. SH-SY5Y cells treated
with the Tat-SabKIM1 had diminished proliferation in a dose-dependent manner;
wherein, 25µM Tat-SabKIM1 slowed proliferation by nearly 40% (Figure 19A). To
determine if decreased proliferation was due to an acute or sustained effect, we
measured cell proliferation daily over five days. SH-SY5Y cells treated with Tat-
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SabKIM1 peptide had reduced proliferation from the initial dosing of the peptide, and
this sustained inhibition was increased dose-dependently (Figure 19B). To assess
whether the decrease in proliferation was due to less cell growth rather than
increased apoptosis, we measured caspase activity in SHSY5Y cells treated with
increasing doses of Tat-SabKIM1. As compared to the positive control [1µM
staurosporine (STS)], Tat-SabKIM1 treatment did not significantly increase caspase
activity (Figure 19C). Thus, decreased Sab-mediated signaling slows proliferation
of SH-SY5Y cells.
3.3 Impaired Sab-mediated signaling decreases the glycolytic rate. Because
proliferation is integrated with cancer metabolism, specifically glycolysis, we
examined the impact of diminished Sab-mediated signaling in neuroblastoma cell
metabolism. We first assessed the glycolytic rate and found that SH-SY5Y cells
treated with 5µM Tat-SabKIM1 for 24 hours had decreased glycolysis (Figure 19D).
Specifically, we noticed a decrease in the basal glycolytic rate and the glycolytic
capacity (Figure 19D & 18E). To verify the decreased extracellular acidification
was due to less lactate production, we measured lactate content in the supernatant
of SH-SY5Y cells treated with either 5µM Tat-Scramble or TatSabKIM1 for 24 hours.
There was a reduction (~25%) in extracellular lactate levels from SH-SY5Y cells
treated with 5µM Tat-SabKIM1 (Figure 19F). To address if the change in glycolysis
was due to altered glucose import into SH-SY5Y cells, we performed a glucose
transport assay (Figure 19G, top panel). We found that treatment with increasing
concentrations of the Tat-SabKIM1 peptide impaired glucose import in a dosedependent manner; however, only a modest change was noted at 5µM Tat-SabKIM1
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(Figure 19G). To determine if the changes in glucose metabolism stemmed from
reduced gene expression, we measured the levels of glycolytic proteins following
24 hours of treatment 5µM TatSabKIM1 (Figure 19H). We didn’t find any discernable
change in protein levels among those surveyed. Consequently, Sab-mediated
signaling may affect glycolysis by post-translational mechanisms.
3.4 Targeting Sab-mediated signaling relieves PDH inhibition. Pyruvate
dehydrogenase (PDH) complex is an important nexus between aerobic glycolysis
and oxidative metabolism; recently, the JNK has been shown to phosphorylate the
PDH E1a subunit and impair enzymatic activity (Zhou et al., 2008; 2009). To
determine if PDH E1a phosphorylation and catalytic activity are altered by
diminished Sab levels, we examined the phosphorylation of PDH E1a in the
presence and absence of the Tat-SabKIM1. Following 24 hours of treatment with
TatSabKIM1, western blotting for PDH E1a revealed two bands in control cells,
which the slower migrating form represents phosphorylated E1a subunit (Figure
20A). SH-SY5Y mitochondria from cells treated with 5µM Tat-SabKIM1 for 24 hours
had less phosphorylated PDH E1a (Figure 20A), which when quantified was nearly
a 50% decrease (Figure 20B). To assess if the change in phosphorylation status
impacted catalysis, we measured PDH activity with increasing concentrations of
Tat-SabKIM1. Inhibition of Sab-mediated signaling enhanced PDH activity in SHSY5Y in a dose-dependent manner (Figure 20C). To determine if this was an effect
exclusive to PDH, we measured the activities of lactate dehydrogenase (Figure
20D) and a-ketoglutarate dehydrogenase (Figure 20E) after 24 hours of treatment
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Figure 19. Inhibition of Sab-mediated signaling slows proliferation and decreases glycolysis.
SH-SY5Y cells were grown in the presence of increasing concentrations of Tat-SabKIM1 or scrambled controls and
proliferation were assessed at day 5 (A) or daily over the course of 5 days (B). The induction of apoptosis in these cells
was measured by caspase assay with STS as a control (C). The glycolytic profile of SH-SY5Y cells treated with 5µM
Tat-SabKIM1 for 24 hours and controls was measured (D) and the basal rate (E) and maximum rate (F) were obtained.
Extracellular lactate levels were measured (G) along with glucose uptake using a near-fluorescent probe (H). The relative
abundance of glycolysis-relevant proteins was measured (I).
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with 5µM TatSabKIM1 peptide, and there was no change in activities for either
enzyme (Figure 20D & 20E). These data imply that impaired Sab-mediated
signaling improves PDH activity.
3.5 Inhibition of Sab-mediated signaling increases oxidative metabolism. To
determine if oxidative metabolism was altered by changing Sab levels, we
measured respiration in the presence and absence of 5µM Tat-SabKIM1 (Figure
20F). Cells treated with the Tat-SabKIM1 had significantly elevated (~20%) basal
respiration (Figure 20G, top panel) and increased (~15%) spare respiratory
capacity (Figure 20G, bottom panel). In Figure 20H, the oxidation of glucose
(Figure 20H, top panel) glutamine (Figure 20H, middle panel) were increased in
the absence of Sab-mediated signaling while, no significant change was observed
in branched-chain amino acid oxidation (Figure 20H, bottom panel). To discern
whether the substrate discrepancies in oxygen consumption were due to changes
in respiratory complex activities, we used biochemical assays and found that only
complex I activity significantly increased after treatment 5µM Tat-SabKIM1 (data not
shown). Further analysis of complex I activity in cells treated with 5µM Tat-SabKIM1
had increased oxygen consumption in the presence of complex I substrates, and
the introduction of 500nM rotenone did not inhibit oxygen consumption to the same
extent as controls (Figure 20I). This effect was not observed with complexes II and
III (Figure 20J). To determine if increased complex I activity was due to elevated
protein levels, we measured the abundance of proteins from each complex and,
no change was observed (Figure 20K). Therefore, Sab-mediated signaling may
suppress oxidative metabolism by inhibiting complex I.
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Figure 20. Diminished Sab-mediated signaling increases oxidative metabolism.
PDH phosphorylation was assessed by western blotting (A) and quantified (B) after treatment with peptides for 24 hours.
PDH activity was also measured in the presence of increasing concentrations of Tat-SabKIM1 and control peptide (C).
LDH and KDH were assayed as well (D). The respiratory profile of cells with and without Sab inhibition was measured
using the Seahorse XF-96 extracellular flux analyzer (D). Basal respiration, spare capacity (E), and oxidation of glucose,
glutamine and isoleucine (F) were measured. Complex I (I) and Complex II/III (J) functions were also measured along
with respiratory protein levels (K) in the presence of Tat-SabKIM1 (24h).
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3.6 Inhibiting Sab-based signaling increases chemoresistance in a Bcl-2
dependent manner. Because of the relationship between JNK and Bcl-2 proteins
(J. W. Chambers et al., 2011a), we examined whether impaired Sab-mediated
signaling altered Bcl-2 family proteins levels. After treatment of SH-SY5Y cells with
5µM Tat-SabKIM1, mitochondria were found to have increased Bcl-2 levels in cells
treated with Tat-SabKIM1 (Figure 21A & 18B). Also, a decrease in Bim levels was
observed (Figures 18A & 18B). To determine if impaired Sab-mediated apoptotic
signaling, we measured viability after treatment with 750nM cisplatin in SH-SY5Y
cells exposed to increasing concentrations of Tat-SabKIM1. Inhibition of Sabmediated signaling improved cell viability in cells treated with cisplatin in a dosedependent manner (Figure 21C). To determine if the cisplatin resistance was
specific or applicable to other drugs, we treated SH-SY5Y cells with chemotherapy
agents following administration of 5µM Tat-SabKIM1. We found that for
cyclophosphamide, doxorubicin, etoposide, and vincristine, inhibiting Sabmediated signaling improved viability (Figure 21D), suggesting that limiting Sabmediated signaling prevents robust induction of apoptosis.
3.7

Increased

Sab

expression

induces

glycolysis

and

enhances

chemosensitivity. To determine if the metabolic and apoptotic changes could be
specifically attributed to Sab levels, we over-expressed Sab in SH-SY5Y cells
(Figure 22A & B), which did not alter mitochondrial density (Figure 22C). We
observed that Sab-overexpressing cells had higher cell numbers (~30%) than
controls (Figure 22D). SH-SY5Y cells with heightened Sab expression had an
increased glycolytic rate (Figure 22E), decreased PDH activity (Figure 22F),
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Figure 21. Impaired Sab-mediated signaling leads to chemoresistance.
Pro-survival (A, left) and pro-apoptotic (A, right) Bcl-2 family protein levels were measured and quantified (B) in the
presence and absence of Sab-mediated signaling (Tat-SabKIM1, 24h). Cytotoxicity of 750nM cisplatin in the presence
and absence of increasing Tat-SabKIM1 was assessed (C). The effect of Sab-inhibition (5µM Tat-SabKIM1 concurrent with
drugs) was examined with 750nM cisplatin, 1µM cyclophosphamide, 100nM doxorubicin, 2.5µM etoposide, and 150nM
vincristine (D).
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reduced basal oxygen consumption (Figure 22G), and less complex I activity
(Figure 4H). We also observed increased ROS generation in mitochondria from
cells overexpressing Sab (Figure 22I). Increasing Sab resulted in a decrease in
Bcl-2 levels and an increase in Bim on mitochondria (Figure 22J), and improved
chemoresponsiveness to cisplatin (Figure 22K) and vincristine (Figure 22L). Thus,
increasing Sab sensitizes neuroblastoma cells to chemotherapy.
3.8 Metabolic and chemoresponsive phenotypes correlate to Sab levels in
neuroblastoma cells. We examined a panel of three neuroblastoma cell lines with
different levels of Sab expression and found that CHP-212 had high Sab
expression, SK-N-SH has a moderate amount of Sab expressing line, and IMR-32
was a low Sab expressing line (Figure 23A). Metabolic analysis of these cell lines
revealed that cells with lower Sab expression had higher OCR/ECAR ratios (Figure
23B) suggesting that the cells were more oxidative. We also examined chemoresponsiveness of the three lines to cisplatin and vincristine, which revealed that
CHP-212 (high Sab levels) was the most sensitive, while IMR-32 (low Sab
expression) had significantly higher cell viability (Figure 23C). Consequently, the
concentration of Sab may be influencing mitochondrial function and apoptosis in
neuroblastoma cells.
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Figure 22. Overexpression of Sab enhances glycolysis and chemoresponsiveness.
Sab was overexpressed in SH-SY5Y cells as confirmed by western blotting (A) and quantitation (B) in regards to
mitochondrial density (C). Proliferation (D), glycolytic rate (E), PDH activity (F), basal respiration (G), complex I activity
(H), and mitochondrial ROS production (I) were measured following 72 hours of transfection. Bcl-2 and Bim levels were
measured (J) in addition to chemosensitivity to cisplatin (K) and 150nM vincristine(L).
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Figure 23. Metabolic and chemoresistant phenotypes correspond to Sab
levels.
Three neuroblastoma lines were subjected to western blotting to detect the relative
abundance of Sab (A), which was normalized to mitochondrial content (B). The
oxidative character of the lines was determined using the OCR/ECAR ratio (C).
Chemosensitivities for the three lines were assessed towards cisplatin and
vincristine (D).
4. Discussion
The MOM scaffold protein Sab has been shown to affect mitochondrial dysfunction
and apoptosis (J. W. Chambers and LoGrasso, 2011; T. P. Chambers et al., 2015).
Our current study expanded the role of Sab-mediated signaling to include
metabolic regulation in neuroblastoma. We found that Sab expression was
reduced in neuroblastoma patients, and diminished Sab-mediated signaling

155

slowed cellular proliferation and decreased glycolysis, and enhanced PDH and
complex I activities. Inhibiting Sab alters mitochondrial Bcl-2 proteins promoting
resistance to chemotherapy-induced apoptosis. Meanwhile, over-expressing Sab
induced proliferation, increased glycolysis, reduced oxidative metabolism, and
enhanced sensitivity to chemotherapeutic drugs. We surmised that decreasing
Sab expression may be part of oncogenesis in neuroblastoma.
The decrease in Sab expression in neuroblastoma patients was significant as
indicated by the impact of Sab-JNK signaling on apoptosis. We believe that the
lack of normal tissue controls, such as fetal brain tissue instead of ganglioneuroma
in many studies, dampened the actual change in Sab expression between
cancerous and non-transformed samples based on the impact of Sab inhibition
and overexpression observed in the cell lines. We predict that Sab levels may be
even lower in neuroblastoma cells than anticipated by this study.
The inhibition of Sab-mediated signaling impaired cellular proliferation and
glycolysis (Figure 19) in neuroblastoma cells. Given that inhibition of Sab-mediated
signaling has been shown not to affect nuclear JNK signaling (J. W. Chambers et
al., 2011a), we surmised that the effects of Sab inhibition were post-translational,
and this notion was supported by the lack of changes in glycolytic and respiratory
protein levels (Figure 19 & 20). Additionally, we found a change in the relative
abundance of phosphorylation on the Ea1 subunit of pyruvate dehydrogenase
(Figure 20). The post-translational impact of JNK signaling has been linked to
glycolysis before; wherein, JNK1 signaling events promote the activity of
phosphofructokinase 1 (PFK1) (Deng et al., 2008). JNK phosphorylation of Bad
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releases PFK-1 allowing for catalysis. Thus, JNK phosphoregulation of Bad and
other glycolytic proteins may be a product of Sab-mediated signaling in
neuroblastoma.
The decreased proliferation by impaired Sab-mediated signaling (Figure 19)
stands in contrast to a study by Fey and colleagues, who found that Akt signaling
inhibits JNK activation in SH-SY5Y cells (Fey et al., 2015). Thus, inhibiting JNK
signaling, including Sab-mediated, may increase Akt-mediated proliferation.
Unfortunately, Fey and colleagues did not investigate if this was an isoformspecific event, so it’s possible that mitochondrial-specific JNK isoforms may not be
affected by Akt signaling but could be by TatSabKIM1. We also see parallels with
our observations and Fey et. al.

For example, suppression of nuclear JNK

signaling by Akt is likely to decrease Sab expression in neuroblastoma. We
recently demonstrated that cells lacking JNK have significantly lower Sab levels
(T. P. Chambers et al., 2015). Akt inhibition of JNK may result in the decreased
Sab expression observed in neuroblastoma patients. Thus, detangling the JNK
isoforms and specific contributions of individual variants to neuroblastoma will be
crucial.
We found that Sab-mediated signaling affects PDH phosphorylation in
neuroblastoma cells (Figure 20A & 22F). This may indicate that active JNK
signaling on Sab in neuroblastoma is contributing to aerobic glycolysis similar to
the aging brain30,42. However, it should be noted that ERK1/2 and p38 isoforms
have been found on mitochondria (Kim et al., 2006; Nowak et al., 2006), and the
KIMs on Sab are MAPK-specific. Similarly, mitochondrial ERK signaling is linked
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to complex I inhibition. Consequently, we cannot rule out the contributions of these
two MAPKs to oxidative metabolism. Despite evidence indicating that
mitochondrial JNK inhibits complex I and amplifies ROS production (J. W.
Chambers and LoGrasso, 2011) through Src (Win et al., 2016), additional studies
are needed to resolve the mechanism of complex I inhibition.
Recently, enhanced Sab-mediated signaling was linked to chemosensitization of
cervical cancer cells (T. P. Chambers et al., 2015), which may have been facilitated
the emigration of Bcl-2 proteins from mitochondria following cytotoxic stress (J. W.
Chambers et al., 2011a). We found that Bcl-2 levels increased following Sab
inhibition in SH-SY5Y cells (Figure 21). We propose that the increase in Bcl-2 and
decrease in Bim in the absence of Sab-mediated signaling are due to diminished
JNK phosphorylation of Bcl-2 and Bim (Putcha et al., 2003). The increased Bcl-2
will prevent Bax/Bak oligomerization and apoptosis. This may explain the chemoresistance in neuroblastoma populations with low Sab expression. We correlated
Sab

levels

to

the

metabolic

phenotype

and

chemoresponsiveness

of

neuroblastoma cells (Figure 23). This result parallels clinical observations that
indicate the robustness of cytotoxic JNK signaling could serve as a prognostic for
neuroblastoma (Fey et al., 2015).
In summary, scaffold protein concentrations, such as Sab, at specific cellular
locations represent the magnitude of the signaling event on an organelle influence
the biological outcomes of signaling (Good et al., 2011). In that regard, we propose
that the relative abundance of Sab on the MOM determines the robustness of JNK
apoptotic signaling and the survival of neuroblastoma cells. Specifically, patients
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with high Sab expression may be more susceptible to therapies and have a greater
likelihood of survival. Chemo-sensitization in high Sab-expressing tumors would
reduce drug doses and minimize the detrimental side-effects in patients.
Ultimately, Sab concentrations ascertained from biopsies or emerging imaging
techniques may be useful to discern appropriate treatment regimens for
neuroblastoma patients.
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1. Summary
Tumors of the central nervous system (CNS) remain some of the most difficult
malignancies to treat because the blood brain barrier can limit the efficacy
chemotherapeutic and immunotherapeutic approaches, but the physiology of
these cancers has yet to be rigorously interrogated due to the difficulty of their
locations. Only recently have techniques been developed to begin to address the
biology of CNS tumors in vivo. By improving the collective understanding of CNS
tumor physiology, one proposes that effective therapeutics can be designed to
target unique aspects of a particular malignancy and improve the survival
outcomes for patients. In our current study, we chose to take a stepwise approach
to dissecting the complexities of tumor physiology and focused on aberrations of
mitochondrial function. Mitochondria are critical to brain function, not only because
they supply 90% of the ATP required by the organ, but because they are central
mediators of neurotransmission and calcium buffering in neurons and modulators
of clearance functions and detoxification reactions in glial cells. In CNS
malignancies, mitochondrial induction of apoptosis may be altered accounting for
the high rates of recurrence and resistance in these disorders. Based on the
important roles for mitochondria in bioenergetic requirements for brain cells and
mediating cell death responses, we focused our studies on these two aspects of
CNS tumor cell physiology.
1.1 Chapter 3 Summary
In our first study (presented in Chapter 3), we examined the bioenergetic
parameters and capacity for apoptosis in ten (10) distinct glioblastoma (GBM) cell
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lines. Real-time metabolic profiling of the established cell lines revealed that there
were no considerable differences in glycolysis and respiration. The metabolic
similarities of the cell lines were corroborated by the examination of protein levels
of glycolytic enzymes, glucose transporters, and monocarboxylate transporters.
Next, we examined if the cell lines exhibited different responsiveness to the
prevailing chemotherapeutic agent temozolomide (TMZ). We were able to
characterize the 10 cell lines as either resistant, responsive, or sensitive to TMZ,
and western blot analysis revealed that there was no difference in O-6methylguanine-DNA methyltransferase (MGMT) levels (a proposed clinical
biomarker) among the cell lines. This lead us to examine the relative abundance
of anti-apoptotic and pro-apoptotic members of the Bcl-2 family of proteins. It has
been previously shown that the concentrations of Bcl-2 family members can
indicate the potential for cells to induce apoptosis as well as represent the relative
sensitivity to therapeutic approaches in solid tumors. Our evaluation found that
differences in the concentrations of anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, and
Mcl-1) and the pro-apoptotic BH3-only protein Bim correlated to the extent of
resistance to TMZ. This observation was verified by inducing chemoresistance in
U87 cells by exposing the cells to hypoxia for 18 hours. The hypoxic treatment
increased the levels of anti-apoptotic Bcl-2 proteins and reduced the concentration
of BIM in U87. Furthermore, pharmacological inhibition of both Bcl-2/Bcl-xL with
ABT-737 (a BIM mimetic) and Mcl-1 with S63A45 effectively induced complete
apoptosis in the 10 established cell lines at a dose of 1µM; however, individual
treatments with either ABT-737 or S63A45 failed to alter cellular viability. To
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determine if these observations corresponded to the apoptotic capacity of GBM in
clinically relevant samples, we profiled expression of Bcl-2 proteins in glioma-like
stem cells (GSCs) recently acquired from patient tumors. We found that with
respect to TMZ exposure the four (4) GSC lines segregated across the same trend.
Whereby, GSCs with high anti-apoptotic Bcl-2 levels and low Bim concentrations
were resistant to TMZ, and cells with low anti-apoptotic proteins and elevated Bim
levels were sensitive to TMZ. Likewise, we found that the GSCs were sensitive to
a combination treatment of ABT-737 and SC63A45, but GSCs were far less
susceptible to individual exposures to the drugs. Our results indicate that GBM
tumors may be subject to BCl-2/BH3-only profiling and determining the apoptotic
capacity of these tumors could represent a means to personalize treatments
depending of the relative abundance of these proteins. Similarly, a combination of
ABT-737 and S62A45 might be a useful approach to sensitize highly resistant
tumors to contemporary therapy options.
1.2 Chapter 4 Summary
In our second study (Chapter 4), we examined the relative concentrations of the
outer mitochondrial membrane (OMM) Sab, which based on our studies in
gynecological cancers, facilitates c-Jun N-terminal Kinase (JNK) signaling on
mitochondria. Increased JNK-Sab signaling was linked to diminished antiapoptotic Bcl-2 levels and elevated BH3-only concentrations on mitochondria
resulting in chemosensitive cancer cells. Our secondary analysis of GBM patient
data revealed that Sab expression (mRNA) was decreased in tumor samples from
patients, and this decrease was consistent across six independent studies. We
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surveyed the 10 GBM cell lines to determine if Sab levels correlated to TMZ
response, and there was absolutely no correlation between Sab concentration and
the sensitivity of cells to TMZ. To determine if this was an artifact of prolonged cell
culture, the GSCs were then analyzed for Sab concentrations, and again, there
was no correlation between Sab abundance and chemoresponsiveness. However,
we did notice the expression of a truncated version of Sab in the 10 established
GBM cell lines that was not present in the GSCs. Using RT-PCR and sequencing,
we found that a second transcript for Sab existed, which had lost the N-terminus
of the protein (1-156). This matches the description for Sab isoform 2 identified
previously in human gene expression studies. Because this splice variant lacks the
original mitochondrial targeting sequence of Sab, we surmised that this variant
may be impairing the ability of GBM cells to induce robust apoptosis. Therefore,
we took SF268 cells and selected for clones that did not express the variant, and
we found one clone (SF268-6) that expressed only full-length Sab. Our analysis
revealed that there was no difference in chemosenstivity towards, TMX, irinotecan,
or mitochondrial toxins. Immunofluerescence later revealed that the Sab-variant
still localized to mitochondria, and this was confirmed by the presence of the
variant protein in mitochondrial isolates. Therefore, the OMM signaling (including
apoptosis) of Sab was still intact. However, previous studies have linked Sabmediated signaling to inhibition of respiratory complex I. Previous topology studies
in the Kaplowitz lab and recent studies in the Chambers lab suggest that the Cterminus of Sab is on the cytosolic face of mitochondria, and the N-terminal
portions reside in the intermembrane space. This model places two coiled-coiled

169

motifs (CC-1 and CC-2) of Sab in the intermembrane space for protein-protein
interactions. However, CC-1 is not present in Sab isoform 2 (the splice variant).
Our examination of SF268 and SF268-6 reveal that SF268 had a faster
proliferation rate than clone 6 (which expresses the full-length Sab only). Reflecting
the increased proliferation rate, SF268 cells had a greater rate of glycolysis that
SF268-6 clones. Further, cells expressing only full-length Sab (SF268-6) had a
30% higher basal respiratory rate that SF268 cells. Moreover, SF268 cells had a
60% lower respiratory capacity than clones with only full-length Sab. Pyruvate
oxidation analysis reveal that the deficiency in oxidative phosphorylation occurs at
the level of complex I. This would suggest that the loss of CC1 in the Sab variant
releases a protein component capable of inhibiting respiration in mammalian cells.
Future studies will be aimed at elucidating the molecular mechanisms of this novel
form of metabolic control.
1.3 Chapter 5 Summary
In our final study, our goal was to determine if the observations in the previous two
studies could be applied to other CNS malignancies, namely CNS-based
neuroblastoma. Using secondary analysis of patient samples, we found that Sab
expression in neuroblastoma was significantly lower than control samples. To
determine if Sab abundance impacted mitochondrial capacity for apoptosis and
cellular metabolism, we overexpressed Sab and a version of Sab (SabKIML-A)
incapable of binding mitogen-activated protein kinases (MAPKs), such as JNK, as
a negative control in human SH-SY5Y neuroblastoma cells. As expected,
increasing Sab expression lead to a decrease in the levels of anti-apoptotic Bcl-2
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proteins and elevated the concentrations of pro-apoptotic BH3-only proteins. This
trend was not observed in the cells expressing SabKIML-A or red-fluorescent protein
(RFP). The increased levels of Sab were sufficient to induce chemo-sensitization
of Sab in the SH-SY5Y cells. With respect to metabolism, ectopic expression of
Sab promoted increased glycolysis in SH-SY5Y cells; meanwhile, elevated Sab
concentrations resulted in decreased respiration and spare respiratory capacity.
The diminished respiration could be linked to inhibition of pyruvate dehydrogenase
(PDH) by JNK phosphorylation on the E1a subunit. Additionally, increased Sab
levels resulted in diminished complex I activity, which appear to be attributed to a
loss of specific complex I components, namely NADH dehydrogenase component,
NDUFS8. Inhibition of Sab mediated signaling with a small peptide (Tat-SabKIM1)
was able to prevent the changes in Bcl-2 proteins and cellular metabolism. Finally,
analysis of three (3) additional CNS-based neuroblastoma cell lines revealed, at
least in this very small sample size, that Sab concentrations correlated to relative
oxidative metabolism phenotypes and susceptibility to cisplatin and vincristine.
These findings suggest that Sab-mediated signaling is a crucial modulator of cell
vulnerability and metabolism in neuroblastoma cells; however, future studies in
patient-derived samples and in mouse models will be useful in determining if these
observations are clinically valid.
1.4 Conclusions
The results of our studies highlight that even in malignancies of the same organ
the molecular mechanisms governing cancer pathogeneses are heterogeneous
and unique among malignancies. While Sab-mediated signaling was not crucial to
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chemo-susceptibility in GBM, Sab-facilitated events were crucial to the induction
of apoptosis in neuroblastoma cells. However, and perhaps more interesting is the
novel metabolic regulation observed in both GBM and neuroblastoma. The direct
impact of Sab-mediated signaling on metabolism may represent a novel metabolic
control point that may be exploited to weaken the bioenergetic capacity of CNS
cancers, and perhaps creating a metabolic conflict may lead to apoptotic priming
effectively rendering tumor cells more vulnerable to therapies. For these reasons,
continued investigation of mitochondrial regulation in CNS cancers is likely to result
in novel therapies capable of extending patient survival and cognitive healthspans.
2. Pitfalls and critical analysis
In the previous chapters, we have tried to highlight the weaknesses and pitfalls in
our studies, and in doing so, we identified key limitations in our studies that could
affect our analyses of the outcomes. There limitations include:
1. The experiments were not conducted in the context of the brain.
2. There are few cell lines and limited patient-derived samples used in the
studies.
3. Many of the analyses conducted are based on endpoint analyses.
4. We were unable to transfect the Sab variant into clone SF268-6 to perform
rescue experiments.
Each limitation will be addressed in more detail in the respective sections below.
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2.1 Studies were performed in a cell autonomous setting.
The prevailing disconnect between the Sab expression studies in GBM patients
and the lack of contribution of Sab to chemo-susceptibility or Bcl-2 protein levels
in GBM cell lines or GSCs may be indicative of working with cells that have been
adapted to culture or isolation of a particular cell population. It is well demonstrated
that tumors are comprised of a very heterogeneous population of cells, and it is
likely the culmination of the collective environment created by the different cell
types that is ultimately responsible for the phenotypes of a particular tumor. Thus,
any technique that isolates and enriches one type is probably not a true depiction
of the tumor. Thereby, when we observe Sab protein levels that are easily detected
by western blotting in cell culture, one may reason that the cells selected for in
culture are not representative GBM tumor cells. Also, the tight correlation between
Sab and the induction of apoptosis in neuroblastoma cells may also not be entirely
reflective of neuroblastoma tumors cells. In fact, the culturing of cells from patient
tumors and sustained culture of established cell lines can be viewed as a selection
process for cells most adept at surviving in a particular set of growth conditions.
Further complicating the use of cell lines is the nutrient-rich media, which in the
right cells can lead to increased metabolism and elevated production of oxidants.
These oxidizing compounds can lead to DNA damage and mutations that may alter
the genetic background of the cell and remove it further from the original
background in the patient tumor. Finally, the tumor microenvironment also plays a
considerable role in the oncogenesis, progression, recurrence, and resistance.
This complex environment is comprised of not only the tumor cells, but also
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immune cells and additional support cells. Without the influence of these
contributors and the products they secrete into the tumor microenvironment, it is
highly unlikely that one could accurately reproduce cell physiology with a single
cell type under robust growth conditions in culture. Therefore, our results should
be taken with these limitations in mind, and our future studies will move to using in
situ systems to better understand how Sab levels influence CNS tumor cell
physiology in the brain.
2.2 Lack of sample numbers and patient context.
Another critical limitation to our studies would be the number of cell lines employed
in the work. The ten GBM cell lines, the four GSC lines, and the four established
CNS-neuroblastoma cell lines are insufficient to generate the statistical power
needed to make relevant correlations between events. A limited number of cells
were used in these studies because the ultimate goal was to move the studies into
a patient-derived animal-based system once funding for the project became
available. It was our intention to take the lessons learned from cell culture and
apply them to the animal models to produce more clinically-relevant data.
Unfortunately, the project was only funded recently, and now the patient derived
animal studies will begin. This approach also highlights another limitation, and that
is the lack of robust patient data related to our cells. Beyond genetic
characterization, many of the patient-relevant information did not accompany the
cells, even the NCI-60 panel. This information may support or contradict some of
the findings, and this information would be crucial when making claims about
personalization. Ultimately, switching into patient-derived in vivo models will fill this
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gap, as our collaborators at Baptist Health South Florida will collect all relevant
patient information, and (at the appropriate time) share it with our team. Thus,
future studies will be supported by significant clinical insights into the samples.
2.3 Studies employed largely endpoint analyses.
Our studies focused primarily on the current state of existing cells lines, at time
points well after the manipulation of Sab expression, or after a prolonged exposure
to chemotherapeutic compounds. It is likely that the pathways we are measuring
are very dynamic and under the controll of synchronized regulation. Therefore, the
physiology of the cell may undergo multiple changes before arriving at the final
measured state. It is possible that one of the intermediate phases may contribute
greatly to the measured event. Perhaps, the manipulation of Sab expression and
treatment with toxic compounds could serve as further selective pressures, and
the resulting cells are a product of these artificial systems making the results less
than reliable. Regardless, future endeavors should consider more kinetic-based
approaches to assay what happens over the course of these treatments not simply
what occurs when a drug is most potent or ectopic expression is at its highest
point.
2.4 Inability to express Sab isoform 2 in SF268-6 cells.
Unfortunately, the major experiment missing from Chapter 4 is the ectopic
expression of Sab isoform 2 in the SF268-6 cells (the clone that only expresses
full-length Sab). Because time was limited, only two attempts were made at
liposome-mediated transfection of a plasmid encoding Sab isoform 2. In the
immediate future, I am anticipating using lentiviruses to introduce the plasmid to

175

the cells and reintroduce Sab isoform 2 into these cells and then monitor the impact
on glycolysis and respiration, with emphasis on complex I.
3. Future directions
Future directions related to this study will primarily consist of using orthotopic
xenografts of patient-derived tumor cells and monitoring mitochondrial physiology
in these tumors. Additionally, perturbations in cancer-specific alterations in
mitochondrial function will be exploited in order to improve therapeutic outcomes
in patients.
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APPENDICES
Supplementary information for chapter 3
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Supplemental figure 1. Expression of metabolic enzymes in GBM cell lines.
GBM cell lines were grown, lysed, and metabolic enzymes protein levels were
assessed by western blot. Expression was normalized to the actin loading control.
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Supplemental Figure 2. Metabolic profiling. The respiratory profile of cells with
and without the Sab splice variant was measured using the Seahorse XF-96
extracellular flux analyzer in the presence of Glucose, Glutamine, and or Pyruvate.
(A) Basal respiration (B) maximum respiration (C) spare capacity (D) basal
glycolysis, (E) maximum glycolysis (F) OCR/ECAR ratio. Comparisons between
groups was performed using the Mann-Whitney test.
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Supplemental Figure 3. MGMT expression in GBM cell lines. GBM cell lines
were grown, lysed, and MGMT protein levels were assessed by western blot
analysis for Bcl-2 family proteins. Expression was normalized to red Ponceau S
staining. (A) Representative western blot. (B) Quantification of normalized protein
expression.
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Supplemental Figure 4. Bcl-2 profiling of GBM cell lines. GBM cell lines were grown, lysed, and protein levels were
assessed by western blot analysis for Bcl-2 family proteins. Expression was normalized to the actin loading control. (A)
Representative western blot. Quantification of normalized protein expression of (B) Bcl-xL, (C) Bad, (D) Bid (E) Bik. Oneway ANOVA was used to determine differences in protein expression between cell lines, p<0.05.
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Supplemental Figure 5. Combination treatment of GBM cell lines with ABT737 and chemotherapeutic drugs. GBM cell lines were incubated for 72 hours in
the presence of 0-5µM of ABT-737, in combination with 125-250µM TMZ, 1-2.5
µM Irinotecan, or 35 µM Carboplatin. The cells were then fixed and stained with
CellTag 700 stain to determine the number of cells. The fluorescence for each drug
combination was plotted.

182

Supplemental Figure 6. Percentage of Cell Viability after treatment with Bcl2 and Mcl-1 inhibitors in GBM Cell Lines. GBM cell lines were incubated for 72
hours in the presence of 0-10µM of ABT-737, 0-10µM S63845, or both. The cells
were then fixed and stained with CellTag 700 stain to determine the number of
cells (A) A172, SF268, (B) SF295, SF539, (C) U87, U118. The fluorescence for
each TMZ dose was plotted (D, E, F, G, H, I) and comparisons between treatments
was performed using ANOVA followed by Tukey’s honest test. ***p<0.001,
****p<0.0001
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Supplemental Figure 7. Percentage of Cell Viability after treatment with Bcl-2 and Mcl-1 inhibitors in Glioma
Stem Cells. GSCs were incubated for 72 hours in the presence of 0-10µM of ABT-737, 0-10µM S63845, or both. The
cells were then fixed and stained with CellTag 700 stain to determine the number of cells. The fluorescence for each
TMZ dose was plotted and comparisons between treatments was performed using ANOVA followed by Tukey’s honest
test. ***p<0.001, ****p<0.0001
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Supplemental Figure 8. Sab expression in Glioma Stem Cells. GSCs were
grown and lysed. Proteins (25µg) were quantified and resolved by SDS-PAGE. (A)
Western blot analysis was used to detect Sab levels. Actin was used as loading
control. (B) Quantification of expression levels.
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